Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Prostate Cancer

  Free Subscription


Articles published in J Urol

Retrieve available abstracts of 779 articles:
HTML format



Single Articles


    May 2021
  1. SHAH N, Ioffe V
    Selecting Patients with Favorable Risk, Grade Group 2 Prostate Cancer for Active Surveillance-Does Magnetic Resonance Imaging Have a Role? Letter.
    J Urol. 2021 May 13:101097JU0000000000001880. doi: 10.1097/JU.0000000000001880.
    PubMed    


    April 2021
  2. RAMAN AG, Sarma KV, Raman SS, Priester AM, et al
    Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer.
    J Urol. 2021 Apr 28:101097JU0000000000001832. doi: 10.1097/JU.0000000000001832.
    PubMed     Abstract available


  3. CHIN JL, Lavi A, Metcalfe MJ, Siddiqui K, et al
    Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer Following Radiation Therapy: A Combined Analysis of Two Centers.
    J Urol. 2021 Apr 28:101097JU0000000000001831. doi: 10.1097/JU.0000000000001831.
    PubMed     Abstract available


  4. LEYH-BANNURAH SR, Liakos N, Oelke M, Wagner C, et al
    Peri- and Postoperative Outcomes of Robot-Assisted Radical Prostatectomy in Prostate Cancer Patients with Prior Transurethral Subvesical Deobstruction: Results of a High-Volume Center.
    J Urol. 2021 Apr 27:101097JU0000000000001776. doi: 10.1097/JU.0000000000001776.
    PubMed     Abstract available


  5. FAN L, Fei X, Zhu Y, Chi C, et al
    Distinct Response to Platinum-Based Chemotherapy Among Patients With Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
    J Urol. 2021 Apr 27:101097JU0000000000001819. doi: 10.1097/JU.0000000000001819.
    PubMed     Abstract available


  6. RAJWA P, Mori K, Huebner NA, Martin DT, et al
    The Prognostic Association of Prostate MRI PI-RADS v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.
    J Urol. 2021 Apr 27:101097JU0000000000001821. doi: 10.1097/JU.0000000000001821.
    PubMed     Abstract available


  7. STABILE A, Sanchez-Salas R, Tourinho-Barbosa R, Macek P, et al
    Association Between Lesion Location and Oncological Outcomes after Focal Therapy for Localized Prostate Cancer Using Either High Intensity Focused Ultrasound or Cryotherapy.
    J Urol. 2021 Apr 23:101097JU0000000000001787. doi: 10.1097/JU.0000000000001787.
    PubMed     Abstract available


  8. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Apr 21:101097JU0000000000001814. doi: 10.1097/JU.0000000000001814.
    PubMed    


  9. ZHANG KW, Reimers MA, Calaway AC, Fradley MG, et al
    Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS).
    J Urol. 2021 Apr 19:101097JU0000000000001785. doi: 10.1097/JU.0000000000001785.
    PubMed     Abstract available


  10. LIN PH, Howard L, Freedland SJ
    Impact of Low Carbohydrate Diet on Self-Report Fatigue and Weakness in Prostate Cancer Patients.
    J Urol. 2021 Apr 5:101097JU0000000000001780. doi: 10.1097/JU.0000000000001780.
    PubMed    


  11. HALABI S, Jiang S, Terasawa E, Garcia-Horton V, et al
    Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
    J Urol. 2021 Apr 5:101097JU0000000000001767. doi: 10.1097/JU.0000000000001767.
    PubMed     Abstract available


  12. MATSUMOTO K, Omura M, Takeda T, Kosaka T, et al
    Grading of Multifocal Prostate Cancer Cases in which the Largest Volume and the Highest Grade do Not Coincide within One Lesion.
    J Urol. 2021 Apr 5:101097JU0000000000001765. doi: 10.1097/JU.0000000000001765.
    PubMed     Abstract available



  13. Erratum: Detection Rate of Prostate Specific Membrane Antigen Tracers for Positron Emission Tomography/Computerized Tomography in Prostate Cancer Biochemical Recurrence: Systematic Review and Network Meta-Analysis.
    J Urol. 2021;205:1237.
    PubMed    


  14. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Apr 1:101097JU0000000000001746. doi: 10.1097/JU.0000000000001746.
    PubMed    


    March 2021
  15. GONG Y, Fan L, Fei X, Zhu Y, et al
    Targeted Next-Generation Sequencing Reveals Heterogenous Genomic Features in Viscerally-Metastatic Prostate Cancer.
    J Urol. 2021 Mar 29:101097JU0000000000001731. doi: 10.1097/JU.0000000000001731.
    PubMed     Abstract available


  16. EASTHAM JA, Heller G, Hillman DW, Hahn OM, et al
    Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance).
    J Urol. 2021 Mar 29:101097JU0000000000001716. doi: 10.1097/JU.0000000000001716.
    PubMed     Abstract available


  17. MCKAY RR, Xie W, Ye H, Fennessy FM, et al
    Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy Prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer.
    J Urol. 2021 Mar 8:101097JU0000000000001702. doi: 10.1097/JU.0000000000001702.
    PubMed     Abstract available


  18. CARROLL PR, Maggi M
    The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer. Reply.
    J Urol. 2021 Mar 8:101097JU0000000000001711. doi: 10.1097/JU.0000000000001711.
    PubMed    


  19. RAJWA P, Pradere B, Mori K, Ploussard G, et al
    Association of Negative Follow-Up Biopsy and Reclassification during Active Surveillance of Prostate Cancer: A Systematic Review and meta-Analysis.
    J Urol. 2021 Mar 8:101097JU0000000000001701. doi: 10.1097/JU.0000000000001701.
    PubMed     Abstract available


  20. MONTORSI F, Gandaglia G, Briganti A
    The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer. Letter.
    J Urol. 2021 Mar 8:101097JU0000000000001710. doi: 10.1097/JU.0000000000001710.
    PubMed    


  21. WENZEL M, Nocera L, Ruvolo CC, Wurnschimmel C, et al
    Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer.
    J Urol. 2021 Mar 8:101097JU0000000000001695. doi: 10.1097/JU.0000000000001695.
    PubMed     Abstract available


  22. BABAJIDE R, Carbunaru S, Nettey OS, Watson KS, et al
    Performance of Prostate Health Index in Biopsy Naive Black Men.
    J Urol. 2021;205:718-724.
    PubMed     Abstract available


  23. UMARI P, Eden C, Cahill D, Rizzo M, et al
    Retzius-Sparing versus Standard Robot-Assisted Radical Prostatectomy: A Comparative Prospective Study of Nearly 500 Patients.
    J Urol. 2021;205:780-790.
    PubMed     Abstract available


  24. TOSOIAN JJ, Trock BJ, Morgan TM, Salami SS, et al
    Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach.
    J Urol. 2021;205:732-739.
    PubMed     Abstract available


  25. MENG X, Chao B, Chen F, Huang R, et al
    Followup of Men with PI-RADS 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy.
    J Urol. 2021;205:748-754.
    PubMed     Abstract available


  26. FEUER Z, Meng X, Rosenkrantz AB, Kasivisvanathan V, et al
    Application of the PRECISION Trial Biopsy Strategy to a Contemporary Magnetic Resonance Imaging-Targeted Biopsy Cohort-How Many Clinically Significant Prostate Cancers are Missed?
    J Urol. 2021;205:740-747.
    PubMed     Abstract available


    February 2021
  27. PIENTA KJ, Gorin MA, Rowe SP, Carroll PR, et al
    A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate-Specific Membrane Antigen PET/CT with (18)F-DCFPyL in Prostate Cancer Patients (OSPREY).
    J Urol. 2021 Feb 26:101097JU0000000000001698. doi: 10.1097/JU.0000000000001698.
    PubMed     Abstract available


  28. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Feb 24:101097JU0000000000001673. doi: 10.1097/JU.0000000000001673.
    PubMed    


  29. BESASIE BD, Sunnapwar AG, Gao F, Troyer D, et al
    Restriction Spectrum Imaging-MRI to Improve Prostate Cancer Imaging in Men on Active Surveillance.
    J Urol. 2021 Feb 22:101097JU0000000000001692. doi: 10.1097/JU.0000000000001692.
    PubMed     Abstract available


  30. ESKRA JN, Rabizadeh D, Zhang J, Isaacs WB, et al
    Specific Detection of Prostate Cancer Cells in Urine by RNA in Situ Hybridization.
    J Urol. 2021 Feb 22:101097JU0000000000001691. doi: 10.1097/JU.0000000000001691.
    PubMed     Abstract available


  31. BRUINSMA SM, Nieboer D, Roobol MJ, Bangma CH, et al
    Risk-Based Selection for Active Surveillance: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Initiative.
    J Urol. 2021 Feb 22:101097JU0000000000001700. doi: 10.1097/JU.0000000000001700.
    PubMed     Abstract available


  32. LINXWEILER J, Sprenk J, Cascetta K, Pryalukhin A, et al
    Robotic Salvage Lymph Node Dissection in Recurrent Prostate Cancer: Lessons Learned from 68 Cases and Implications for Future Clinical Management.
    J Urol. 2021 Feb 22:101097JU0000000000001697. doi: 10.1097/JU.0000000000001697.
    PubMed     Abstract available


  33. SOUNTOULIDES P, Pyrgidis N, Polyzos SA, Mykoniatis I, et al
    Micro-Ultrasound-guided Versus Multiparametric Magnetic Resonance Imaging-Targeted Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-Analysis.
    J Urol. 2021 Feb 12:101097JU0000000000001639. doi: 10.1097/JU.0000000000001639.
    PubMed     Abstract available


  34. KHRIGUIAN J, Tsui JMG, Vaughan R, Kucharczyk MJ, et al
    The Clinical Significance of Bone Mineral Density Changes Following Long Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients.
    J Urol. 2021 Feb 12:101097JU0000000000001646. doi: 10.1097/JU.0000000000001646.
    PubMed     Abstract available


  35. MEIJER D, de Barros HA, van Leeuwen PJ, Bodar YJL, et al
    The Predictive Value of Preoperative Negative PSMA PET Imaging for Lymph-Node Metastatic Prostate Cancer.
    J Urol. 2021 Feb 3:101097JU0000000000001592. doi: 10.1097/JU.0000000000001592.
    PubMed     Abstract available



  36. Erratum: PI-RADS(R) Category as Predictor of Progression to Unfavorable Risk Prostate Cancer in Men on Active Surveillance.
    J Urol. 2021;205:638.
    PubMed    


  37. ATALA A
    Uro-Science.
    J Urol. 2021;205:632-633.
    PubMed    


  38. KOHAAR I, Chen Y, Banerjee S, Borbiev T, et al
    A Urine Exosome Gene Expression Panel Distinguishes between Indolent and Aggressive Prostate Cancers at Biopsy.
    J Urol. 2021;205:420-425.
    PubMed     Abstract available


    January 2021
  39. CAI PY, Ma X, Christos P, Barbieri CE, et al
    Understanding the True Prevalence of Prostate Cancer Genomic Subtypes: Use of Inverse Probability Weighting to Correct for Biases in Molecularly Profiled Cohorts.
    J Urol. 2021 Jan 27:101097JU0000000000001627. doi: 10.1097/JU.0000000000001627.
    PubMed    


  40. MCKAY RR, Berchuck J, Kwak L, Xie W, et al
    Outcomes Post Neoadjuvant Intense Hormone Therapy and Surgery for Patients with High-Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials.
    J Urol. 2021 Jan 27:101097JU0000000000001632. doi: 10.1097/JU.0000000000001632.
    PubMed     Abstract available


  41. GUO B, Liu M
    Evaluation of Cancer Specific Mortality With Surgery Versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger Than 60 Years. Letter.
    J Urol. 2021 Jan 22:101097JU0000000000001636. doi: 10.1097/JU.0000000000001636.
    PubMed    


  42. WANG S, Siddiqui MM
    Evaluation of Cancer Specific Mortality With Surgery Versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger Than 60 Years. Reply.
    J Urol. 2021 Jan 22:101097JU0000000000001637. doi: 10.1097/JU.0000000000001637.
    PubMed    


  43. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2021 Jan 22:101097JU0000000000001620. doi: 10.1097/JU.0000000000001620.
    PubMed    


  44. NGUYEN DD, Haeuser L, Paciotti M, Reitblat C, et al
    Systematic Review of Time to Definitive Treatment for Intermediate-Risk and High-Risk Prostate Cancer: Are Delays Associated with Worse Outcomes?
    J Urol. 2021 Jan 14:101097JU0000000000001601. doi: 10.1097/JU.0000000000001601.
    PubMed     Abstract available


  45. TAN HJ
    Re:A Patient-Reported vs. Claims-Based Measures of Health for Modeling Life Expectancy in Men with Prostate Cancer.
    J Urol. 2021 Jan 14:101097JU0000000000001600. doi: 10.1097/JU.0000000000001600.
    PubMed    


  46. FROEHNER M
    Patient Reported vs Claims Based Measures of Health for Modeling Life Expectancy in Men with Prostate Cancer. Letter.
    J Urol. 2021 Jan 14:101097JU0000000000001599. doi: 10.1097/JU.0000000000001599.
    PubMed    



  47. Erratum: Does Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
    J Urol. 2021;205:278.
    PubMed    


  48. CHU C, Carroll P
    Editorial Comment.
    J Urol. 2021;205:121.
    PubMed    


  49. CHU CE, Cowan JE, Fasulo V, Washington SL 3rd, et al
    The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance-Does Cancer Vanish or Simply Hide?
    J Urol. 2021;205:109-114.
    PubMed     Abstract available


  50. ICZKOWSKI KA, van Leenders GJLH
    Eight Endorsements of the International Society of Urological Pathology from the 2019 Consensus Conference on Grading of Prostatic Carcinoma.
    J Urol. 2021;205:8-10.
    PubMed    


    December 2020
  51. ARMSTRONG AJ, Shore ND, Szmulewitz RZ, Petrylak DP, et al
    Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.
    J Urol. 2020 Dec 28:101097JU0000000000001568. doi: 10.1097/JU.0000000000001568.
    PubMed     Abstract available


  52. YERRAM NK, Long L, O'Connor LP, Wang AZ, et al
    MRI-Targeted and Systematic Biopsy for Detection of Grade Progression in Patients on Active Surveillance for Prostate Cancer.
    J Urol. 2020 Dec 24:101097JU0000000000001547. doi: 10.1097/JU.0000000000001547.
    PubMed     Abstract available


  53. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2020 Dec 23:101097JU0000000000001564. doi: 10.1097/JU.0000000000001564.
    PubMed    


  54. NAHA U, Nickel JC, Andriole GL, Freedland SJ, et al
    Re: Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE Study.
    J Urol. 2020 Dec 22:101097JU0000000000001588. doi: 10.1097/JU.0000000000001588.
    PubMed    


  55. WILT TJ, Ullman KE, Linskens EJ, MacDonald R, et al
    Therapies for Clinically Localized Prostate Cancer: A Comparative Effectiveness Review.
    J Urol. 2020 Dec 22:101097JU0000000000001578. doi: 10.1097/JU.0000000000001578.
    PubMed     Abstract available


  56. STAVRINIDES V, Freeman A, Ball R, Haider A, et al
    Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE Study.
    J Urol. 2020 Dec 22:101097JU0000000000001587. doi: 10.1097/JU.0000000000001587.
    PubMed    


  57. PIERRE-VICTOR D, Pinsky PF, Miller E, Parnes H, et al
    Other- and All-Cause Mortality Among Men Diagnosed with Prostate Cancer in the PLCO Trial.
    J Urol. 2020 Dec 22:101097JU0000000000001531. doi: 10.1097/JU.0000000000001531.
    PubMed     Abstract available


  58. SHORE N, Oliver L, Shui I, Gayle A, et al
    Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated HRR Gene Alterations.
    J Urol. 2020 Dec 17:101097JU0000000000001570. doi: 10.1097/JU.0000000000001570.
    PubMed     Abstract available


  59. ORCZYK C, Barratt D, Brew-Graves C, Peng Hu Y, et al
    Prostate Radiofrequency Focal Ablation (ProRAFT) Trial: A Prospective Development Study Evaluating a Bipolar Radiofrequency Device to Treat Prostate Cancer.
    J Urol. 2020 Dec 14:101097JU0000000000001567. doi: 10.1097/JU.0000000000001567.
    PubMed     Abstract available


  60. MAGGI M, Cowan JE, Fasulo V, Washington SL 3rd, et al
    The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
    J Urol. 2020;204:1222-1228.
    PubMed     Abstract available


  61. EHDAIE B
    Editorial Comment.
    J Urol. 2020;204:1234-1235.
    PubMed    


  62. DALL'ERA MA
    Editorial Comment.
    J Urol. 2020;204:1194.
    PubMed    


  63. MORASH C
    Editorial Comment.
    J Urol. 2020;204:1221.
    PubMed    


  64. ATALA A
    Re: Regenerative Potential of Prostate Luminal Cells Revealed by Single-Cell Analysis.
    J Urol. 2020;204:1384.
    PubMed    


  65. JAZAYERI SB, Balaji KC
    Re: Antibiotic Prophylaxis for the Prevention of Infectious Complications following Prostate Biopsy: A Systematic Review and Meta-AnalysisA. Pilatz, K. Dimitropoulos, R. Veeratterapillay, Y. Yuan, M. I. Omar, S. MacLennan, T. Cai, F. Bruyere, R. Barto
    J Urol. 2020;204:1349-1350.
    PubMed    


  66. GINSBURG KB, Cher ML, Montie JE
    Defining Quality Metrics for Active Surveillance: The Michigan Urological Surgery Improvement Collaborative Experience.
    J Urol. 2020;204:1119-1121.
    PubMed    


  67. MARRA G, Zhuang J, Marquis A, Zhao X, et al
    Pain in Men Undergoing Transperineal Free-Hand Multiparametric Magnetic Resonance Imaging Fusion Targeted Biopsies under Local Anesthesia: Outcomes and Predictors from a Multicenter Study of 1,008 Patients.
    J Urol. 2020;204:1209-1215.
    PubMed     Abstract available


  68. CONNOR MJ, Eldred-Evans D, van Son M, Hosking-Jervis F, et al
    A Multicenter Study of the Clinical Utility of Nontargeted Systematic Transperineal Prostate Biopsies in Patients Undergoing Pre-Biopsy Multiparametric Magnetic Resonance Imaging.
    J Urol. 2020;204:1195-1201.
    PubMed     Abstract available


  69. CULLEN J, Lynch JA, Klein EA, Van Den Eeden SK, et al
    Multicenter Comparison of 17-Gene Genomic Prostate Score as a Predictor of Outcomes in Black and White Men with Clinically Localized Prostate Cancer.
    J Urol. 2020 Dec 1:101097JU0000000000001484. doi: 10.1097/JU.0000000000001484.
    PubMed     Abstract available


  70. MEYER AR, Mamawala M, Winoker JS, Landis P, et al
    Transperineal Prostate Biopsy Improves the Detection of Clinically Significant Prostate Cancer among Men on Active Surveillance.
    J Urol. 2020 Dec 1:101097JU0000000000001523. doi: 10.1097/JU.0000000000001523.
    PubMed     Abstract available


    November 2020
  71. STONE BV, Laviana AA, Luckenbaugh AN, Huang LC, et al
    Patient-Reported Financial Toxicity Associated with Contemporary Treatment for Localized Prostate Cancer.
    J Urol. 2020 Nov 30:101097JU0000000000001423. doi: 10.1097/JU.0000000000001423.
    PubMed     Abstract available


  72. DEWITT-FOY ME, Gam K, Modlin C, Kim SP, et al
    Race, Decisional Regret and Prostate Cancer Beliefs: Identifying Targets to Reduce Racial Disparities in Prostate Cancer.
    J Urol. 2020 Nov 23:101097JU0000000000001385. doi: 10.1097/JU.0000000000001385.
    PubMed     Abstract available


  73. STONIER T, Tin AL, Sjoberg DD, Jibara G, et al
    Selecting Patients with Favourable-Risk, GG2 Prostate Cancer for Active Surveillance: Does MRI Have a Role?
    J Urol. 2020 Nov 20:101097JU0000000000001519. doi: 10.1097/JU.0000000000001519.
    PubMed     Abstract available


  74. CHEN M, Zhuang J, Fu Y, Guo S, et al
    Can (68)Ga-PSMA-11 PET/CT Predict Pathologic Response of Primary Prostate Cancer to Neoadjuvant Androgen Deprivation Therapy: A Pilot Study.
    J Urol. 2020 Nov 18:101097JU0000000000001481. doi: 10.1097/JU.0000000000001481.
    PubMed     Abstract available


  75. MEIJER D, Luiting HB, van Leeuwen PJ, Remmers S, et al
    PSMA PET/CT in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer.
    J Urol. 2020 Nov 18:101097JU0000000000001437. doi: 10.1097/JU.0000000000001437.
    PubMed     Abstract available


  76. KHOO CC, Eldred-Evans D, Peters M, van Son M, et al
    A Comparison of Prostate Cancer Detection Between Visual-Estimation (Cognitive Registration) and Image-Fusion (Software Registration) Targeted Transperineal Prostate Biopsy.
    J Urol. 2020 Nov 18:101097JU0000000000001476. doi: 10.1097/JU.0000000000001476.
    PubMed     Abstract available


  77. WIBMER AG, Chaim J, Lakhman Y, Lefkowitz R, et al
    Oncologic Outcomes after Localized Prostate Cancer Treatment: Associations with Pre-treatment Prostate MRI Findings.
    J Urol. 2020 Nov 18:101097JU0000000000001474. doi: 10.1097/JU.0000000000001474.
    PubMed     Abstract available


  78. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2020 Nov 17:101097JU0000000000001501. doi: 10.1097/JU.0000000000001501.
    PubMed    


  79. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2020 Nov 12:101097JU0000000000001472. doi: 10.1097/JU.0000000000001472.
    PubMed    


  80. POWELL IJ, Heilbrun LK, Kittles RA
    RE: African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from Canary Prostate Cancer Active Surveillance Study.
    J Urol. 2020 Nov 6:101097JU0000000000001443. doi: 10.1097/JU.0000000000001443.
    PubMed    


  81. SCHENK JM, Newcomb LF, Zhu K, Zheng Y, et al
    Re: African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study.
    J Urol. 2020 Nov 6:101097JU0000000000001444. doi: 10.1097/JU.0000000000001444.
    PubMed    



  82. Erratum: Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop.
    J Urol. 2020;204:1069.
    PubMed    


  83. BIANCO FJ JR
    Editorial Comment.
    J Urol. 2020;204:948-949.
    PubMed    


  84. CATHELINEAU X, Sanchez-Salas R
    Editorial Comment.
    J Urol. 2020;204:949.
    PubMed    


  85. BASILE G, Bandini M
    Editorial Comment.
    J Urol. 2020;204:967-968.
    PubMed    


  86. PREISSER F
    Editorial Comment.
    J Urol. 2020;204:967.
    PubMed    


  87. MIURA N, Mori K, Mostafaei H, Quhal F, et al
    The Prognostic Impact of Intraductal Carcinoma of the Prostate: A Systematic Review and Meta-Analysis.
    J Urol. 2020;204:909-917.
    PubMed     Abstract available


  88. KANTHABALAN A, Arya M, Freeman A, Mitra AV, et al
    Intraprostatic Cancer Recurrence following Radical Radiotherapy on Transperineal Template Mapping Biopsy: Implications for Focal Ablative Salvage Therapy.
    J Urol. 2020;204:950-955.
    PubMed     Abstract available


  89. PLOUSSARD G, Dumonceau O, Thomas L, Benamran D, et al
    Multi-Institutional Assessment of Routine Same Day Discharge Surgery for Robot-Assisted Radical Prostatectomy.
    J Urol. 2020;204:956-961.
    PubMed     Abstract available


  90. MONAGHAN TF, Weiss JP, Wein AJ
    Re: Impact of Nocturia on Mortality: The Nagahama StudyS. Funada, Y. Tabara, K. Setoh, H. Negoro, S. Akamatsu, T. Yoshino, K. Yoshimura, N. Watanabe, T. A. Furukawa, F. Matsuda and O. Ogawa J Urol 2020; doi: 10.1097/JU.0000000000001138.
    J Urol. 2020;204:1067-1068.
    PubMed    


    October 2020
  91. CRAWFORD ED, Hafron JM, Tagawa ST, Twardowski PW, et al
    Impact of Late Dosing on Testosterone Suppression with Two Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere - An Analysis of US Clinical Data.
    J Urol. 2020 Oct 22:101097JU0000000000001392. doi: 10.1097/JU.0000000000001392.
    PubMed     Abstract available


  92. BUISSET J, Norris JM, Puech P, Leroy X, et al
    Negative Pre-biopsy Magnetic Resonance Imaging and Risk of Significant Prostate Cancer: Baseline and Long-Term Follow-up Results.
    J Urol. 2020 Oct 20:101097JU0000000000001414. doi: 10.1097/JU.0000000000001414.
    PubMed     Abstract available


  93. NAHA U, Nickel JC, Andriole GL, Freedland SJ, et al
    Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE Study.
    J Urol. 2020 Oct 20:101097JU0000000000001407. doi: 10.1097/JU.0000000000001407.
    PubMed     Abstract available


  94. XU MC, Huelster HL, Hatcher JB, Avulova S, et al
    Obesity is Associated with Longer Survival Independent of Sarcopenia and Myosteatosis in Metastatic and/or Castrate-Resistant Prostate Cancer.
    J Urol. 2020 Oct 20:101097JU0000000000001428. doi: 10.1097/JU.0000000000001428.
    PubMed     Abstract available


  95. PATEL A
    Does Baseline Serum Testosterone Influence Androgen Deprivation Therapy Outcomes in Hormone Naive Advanced Prostate Cancer Patients?
    J Urol. 2020 Oct 9:101097JU0000000000001413. doi: 10.1097/JU.0000000000001413.
    PubMed     Abstract available


  96. CARLSSON SV, Touijer K
    Re: Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience.
    J Urol. 2020 Oct 9:101097JU0000000000001421. doi: 10.1097/JU.0000000000001421.
    PubMed    


  97. MONTORSI F, Gandaglia G, Fossati N, Briganti A, et al
    Re: Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience. J Urol. 2020;203(6):1122-7.
    J Urol. 2020 Oct 9:101097JU0000000000001420. doi: 10.1097/JU.0000000000001420.
    PubMed    


  98. POOLI A, Johnson DC, Shirk J, Markovic D, et al
    Predicting Pathologic Tumor Size in Prostate Cancer Based on Multiparametric Prostate MRI and Preoperative Findings.
    J Urol. 2020 Oct 7:101097JU0000000000001389. doi: 10.1097/JU.0000000000001389.
    PubMed     Abstract available



  99. Re: Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer.
    J Urol. 2020 Oct 7:101097JU0000000000001403. doi: 10.1097/JU.0000000000001403.
    PubMed    


  100. MOROTE J, Comas I
    Re: Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer.
    J Urol. 2020 Oct 7:101097JU0000000000001402. doi: 10.1097/JU.0000000000001402.
    PubMed    


  101. RIBEIRO L, Stonier T, Stroman L, Tourinho-Barbosa R, et al
    Is the Toxicity of Salvage Prostatectomy Related to the Primary Prostate Cancer Therapy Received?
    J Urol. 2020 Oct 6:101097JU0000000000001382. doi: 10.1097/JU.0000000000001382.
    PubMed     Abstract available


  102. KLOTZ L, Pavlovich CP, Chin J, Hatiboglu G, et al
    MRI-guided transurethral ultrasound ablation of prostate cancer.
    J Urol. 2020 Oct 6:101097JU0000000000001362. doi: 10.1097/JU.0000000000001362.
    PubMed     Abstract available


  103. ABREU AL, Peretsman S, Iwata A, Shakir A, et al
    High Intensity Focused Ultrasound Hemigland Ablation for Prostate Cancer: Initial Outcomes of a United States Series.
    J Urol. 2020;204:741-747.
    PubMed     Abstract available


  104. GINSBURG KB, Curtis GL, Timar RE, George AK, et al
    Delayed Radical Prostatectomy is Not Associated with Adverse Oncologic Outcomes: Implications for Men Experiencing Surgical Delay Due to the COVID-19 Pandemic.
    J Urol. 2020;204:720-725.
    PubMed     Abstract available


  105. HELFAND BT, Glaser AP
    Editorial Comment.
    J Urol. 2020;204:700.
    PubMed    


  106. LOPEZ F, Macpherson R, Lamb A
    Editorial Comment.
    J Urol. 2020;204:670.
    PubMed    


  107. VALERIO M
    Editorial Comment.
    J Urol. 2020;204:747.
    PubMed    


  108. BARBIERI CE
    Editorial Comment.
    J Urol. 2020;204:712-713.
    PubMed    


  109. MANO R
    Editorial Comment.
    J Urol. 2020;204:713.
    PubMed    


  110. GINSBURG KB, Curtis GL, Timar RE, George AK, et al
    Reply by Authors.
    J Urol. 2020;204:845.
    PubMed    


  111. SCHMIDT A, Warmann SW, Eckert F, Ellerkamp V, et al
    The Role of Reconstructive Surgery and Brachytherapy in Pediatric Bladder/Prostate Rhabdomyosarcoma.
    J Urol. 2020;204:825-834.
    PubMed     Abstract available


  112. LISS MA, Newcomb LF, Zheng Y, Garcia MP, et al
    Magnetic Resonance Imaging for the Detection of High Grade Cancer in the Canary Prostate Active Surveillance Study.
    J Urol. 2020;204:701-706.
    PubMed     Abstract available


  113. RODRIGUEZ SOCARRAS ME, Gomez Rivas J, Cuadros Rivera V, Reinoso Elbers J, et al
    Prostate Mapping for Cancer Diagnosis: The Madrid Protocol. Transperineal Prostate Biopsies Using Multiparametric Magnetic Resonance Imaging Fusion and Micro-Ultrasound Guided Biopsies.
    J Urol. 2020;204:726-733.
    PubMed     Abstract available


    September 2020
  114. CHUANG R, Kinnaird A, Kwan L, Sisk A, et al
    Hemigland Cryoablation of Clinically Significant Prostate Cancer: Intermediate-Term Followup via Magnetic Resonance Imaging Guided Biopsy.
    J Urol. 2020 Sep 28:101097JU0000000000001133. doi: 10.1097/JU.0000000000001133.
    PubMed     Abstract available


  115. TANEJA SS
    Re: Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-Focused Panel.
    J Urol. 2020 Sep 22:101097JU0000000000001283. doi: 10.1097/JU.0000000000001283.
    PubMed    


  116. TANEJA SS
    Re: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis.
    J Urol. 2020 Sep 22:101097JU000000000000128302.
    PubMed    


  117. TANEJA SS
    Re: Facility-Level Variation in Pelvic Lymphadenectomy during Radical Prostatectomy and Effect on Overall Survival in Men with High-Risk Prostate Cancer.
    J Urol. 2020 Sep 22:101097JU000000000000128301.
    PubMed    


  118. LOWRANCE WT, Breau RH, Chou R, Chapin BF, et al
    Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.
    J Urol. 2020 Sep 22:101097JU0000000000001375. doi: 10.1097/JU.0000000000001375.
    PubMed     Abstract available


  119. LOWRANCE WT, Breau RH, Chou R, Chapin BF, et al
    Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II.
    J Urol. 2020 Sep 22:101097JU0000000000001376. doi: 10.1097/JU.0000000000001376.
    PubMed     Abstract available


  120. ELLIOTT SP
    Re: Magnetic Resonance Imaging Features of Pubic Symphysis Urinary Fistula with Pubic Bone Osteomyelitis in the Treated Prostate Cancer Patient.
    J Urol. 2020 Sep 21:101097JU000000000000127901.
    PubMed    


  121. SIEGEL C
    Re: Development and External Validation of Multiparametric MRI-Derived Nomogram to Predict Risk of Pathologic Upgrade in Patients on Active Surveillance for Prostate Cancer.
    J Urol. 2020 Sep 21:101097JU0000000000001271. doi: 10.1097/JU.0000000000001271.
    PubMed    


  122. CROCEROSSA F, Marchioni M, Novara G, Carbonara U, et al
    Detection Rate of Prostate-Specific Membrane Antigen Tracers for Positron Emission Tomography/Computed Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis.
    J Urol. 2020 Sep 16:101097JU0000000000001369. doi: 10.1097/JU.0000000000001369.
    PubMed     Abstract available


  123. TAN HJ, Zhou X, Spratte BN, McMahon S, et al
    Patient-Reported vs. Claims-Based Measures of Health for Modeling Life Expectancy in Men with Prostate Cancer.
    J Urol. 2020 Sep 10:101097JU0000000000001355. doi: 10.1097/JU.0000000000001355.
    PubMed     Abstract available


  124. FAN L, Fei X, Zhu Y, Pan J, et al
    Comparative analysis of genomic alterations across castration-sensitive and castration-resistant prostate cancer via circulating tumor DNA sequencing.
    J Urol. 2020 Sep 8:101097JU0000000000001363. doi: 10.1097/JU.0000000000001363.
    PubMed     Abstract available


  125. DE LA CALLE CM, Fasulo V, Cowan JE, Lonergan PE, et al
    Clinical Utility of 4Kscore, ExosomeDx and Magnetic Resonance Imaging for the Early Detection of High-Grade Prostate Cancer.
    J Urol. 2020 Sep 8:101097JU0000000000001361. doi: 10.1097/JU.0000000000001361.
    PubMed     Abstract available


  126. CHEN Y, Wu X, Yan W
    RE: Tumor Location and Pathological Features of Latent and Incidental Prostate Cancer in Contemporary Japanese Men.
    J Urol. 2020 Sep 8:101097JU0000000000001348. doi: 10.1097/JU.0000000000001348.
    PubMed    


  127. KLEIN EA, Li J, Milinovich A, Schold JD, et al
    Androgen Deprivation Therapy in Men With Prostate Cancer Does Not Affect Risk of Infection With SARS-CoV-2.
    J Urol. 2020 Sep 8:101097JU0000000000001338. doi: 10.1097/JU.0000000000001338.
    PubMed     Abstract available


  128. TANEJA SS
    Re: Association of Presalvage Radiotherapy PSA Levels after Prostatectomy with Outcomes of Long-Term Antiandrogen Therapy in Men with Prostate Cancer.
    J Urol. 2020 Sep 8:101097JU0000000000001261. doi: 10.1097/JU.0000000000001261.
    PubMed    


  129. TANEJA SS
    Re: Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
    J Urol. 2020 Sep 8:101097JU000000000000126101.
    PubMed    


  130. ALGHAZO O, Cumberbatch M, Murphy DG
    Editorial Comment.
    J Urol. 2020;204:502.
    PubMed    


  131. VILLERS A, Olivier J
    Editorial Comment.
    J Urol. 2020;204:489.
    PubMed    


  132. SIEGEL C
    Re: Classification of Cancer at Prostate MRI: Deep Learning versus Clinical PI-RADS Assessment.
    J Urol. 2020;204:597.
    PubMed    


  133. HELFAND B
    Editorial Comment.
    J Urol. 2020;204:474-475.
    PubMed    


  134. MONTORSI F, Capogrosso P
    Re: The Impact of Nocturia on Mortality: A Systematic Review and Meta-AnalysisJ. S. Pesonen, R. Cartwright, R. W. M. Vernooij, Y. Aoki, A. Agarwal, A. Mangera, A. D. Markland, J. F. Tsui, H. Santti, T. L. Griebling, A. E. Pryalukhin, J. Riikonen, R. M
    J Urol. 2020;204:589-590.
    PubMed    


  135. AHMAD AE, Richard PO, Leao R, Hajiha M, et al
    Does Time Spent on Active Surveillance Adversely Affect the Pathological and Oncologic Outcomes in Patients Undergoing Delayed Radical Prostatectomy?
    J Urol. 2020;204:476-482.
    PubMed     Abstract available


  136. DASKIVICH TJ, Howard LE, Amling CL, Aronson WJ, et al
    Competing Risks of Mortality among Men with Biochemical Recurrence after Radical Prostatectomy.
    J Urol. 2020;204:511-517.
    PubMed     Abstract available


  137. LUITING HB, van Leeuwen PJ, Remmers S, Donswijk M, et al
    Optimal Timing of Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Biochemical Recurrence after Radical Prostatectomy.
    J Urol. 2020;204:503-510.
    PubMed     Abstract available


  138. SAIDIAN A, Fang AM, Hakim O, Magi-Galluzzi C, et al
    Perioperative Outcomes of Single vs Multi-Port Robotic Assisted Radical Prostatectomy: A Single Institutional Experience.
    J Urol. 2020;204:490-495.
    PubMed     Abstract available


    August 2020
  139. SARI MOTLAGH R, Quhal F, Mori K, Miura N, et al
    The Risk of New Onset Dementia And/Or Alzheimer's Disease Among Prostate Cancer Patients Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-analysis.
    J Urol. 2020 Aug 28:101097JU0000000000001341. doi: 10.1097/JU.0000000000001341.
    PubMed     Abstract available


  140. GRIEBLING TL
    Re: Frailty Syndrome is Associated with Changes in Peripheral Inflammatory Markers in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy.
    J Urol. 2020 Aug 26:101097JU000000000000124803.
    PubMed    


  141. GRIEBLING TL
    Re: Androgen Deprivation Therapy for Prostate Cancer and Risk of Dementia.
    J Urol. 2020 Aug 26:101097JU000000000000124804.
    PubMed    


  142. GRIEBLING TL
    Re: Is There a Benefit of Additional Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years with Hormone-Sensitive Advanced Prostate Cancer? A Meta-Analysis.
    J Urol. 2020 Aug 26:101097JU0000000000001248. doi: 10.1097/JU.0000000000001248.
    PubMed    


  143. GRIEBLING TL
    Re: Pre-Diagnostic Serum Metabolomic Profiling of Prostate Cancer Survival.
    J Urol. 2020 Aug 26:101097JU000000000000124801.
    PubMed    


  144. GRIEBLING TL
    Re: Clinical-Genomic Characterization Unveils More Aggressive Disease Features in Elderly Prostate Cancer Patients with Low-Grade Disease.
    J Urol. 2020 Aug 26:101097JU000000000000124802.
    PubMed    


  145. ATALA A
    Re: Noncoding Mutations Target Cis-Regulatory Elements of the FOXA1 Plexus in Prostate Cancer.
    J Urol. 2020 Aug 21:101097JU0000000000001263. doi: 10.1097/JU.0000000000001263.
    PubMed    


  146. ATALA A
    Re: Genome-Wide Plasma DNA Methylation Features of Metastatic Prostate Cancer.
    J Urol. 2020 Aug 21:101097JU000000000000126301.
    PubMed    


  147. BORGES RC, Tourinho-Barbosa RR, Glina S, Macek P, et al
    Impact of Focal Versus Whole Gland Ablation for Prostate Cancer on Sexual Function and Urinary Continence.
    J Urol. 2020 Aug 17:101097JU0000000000001327. doi: 10.1097/JU.0000000000001327.
    PubMed     Abstract available


  148. PANER GP
    Editorial Comment.
    J Urol. 2020;204:265-266.
    PubMed    


  149. EGGENER S
    Editorial Comment.
    J Urol. 2020;204:287.
    PubMed    


  150. REESE AC
    Editorial Comment.
    J Urol. 2020;204:302.
    PubMed    


  151. CHANDRASEKAR T
    Editorial Comment.
    J Urol. 2020;204:301-302.
    PubMed    


  152. NYAME YA
    Editorial Comment.
    J Urol. 2020;204:280.
    PubMed    


  153. MORASH C
    Editorial Comment.
    J Urol. 2020;204:279-280.
    PubMed    


  154. BRONKEMA C, Arora S, Sood A, Dalela D, et al
    Rare Histological Variants of Prostate Adenocarcinoma: A National Cancer Database Analysis.
    J Urol. 2020;204:260-266.
    PubMed     Abstract available


  155. WOON DTS, Herrera-Caceres JO, Goldberg H, Shiakh H, et al
    A High Percent Free Prostate Specific Antigen in the Setting of Biochemical Recurrence after Radical Prostatectomy is Associated with Poorer Outcomes: A Validation Study Using Prospectively Collected Biobank Specimens.
    J Urol. 2020;204:289-295.
    PubMed     Abstract available


    July 2020
  156. GREGG JR, Surasi DS, Childs A, Moll N, et al
    The Association of Peri-Prostatic Fat and Grade Group Progression in Men with Localized Prostate Cancer on Active Surveillance.
    J Urol. 2020 Jul 27:101097JU0000000000001321. doi: 10.1097/JU.0000000000001321.
    PubMed     Abstract available


  157. PARK KJ, Choi SH, Lee JS, Kim JK, et al
    Risk Stratification of Prostate Cancer According to PI-RADS Version 2 Categories: Meta-Analysis for Prospective Studies.
    J Urol. 2020 Jul 27:101097JU0000000000001306. doi: 10.1097/JU.0000000000001306.
    PubMed     Abstract available


  158. SONG G, Ruan M, Wang H, Fan Y, et al
    How Many Targeted Biopsy Cores are Needed for Clinically Significant Prostate Cancer Detection during Transperineal Magnetic Resonance Imaging Ultrasound Fusion Biopsy?
    J Urol. 2020 Jul 27:101097JU0000000000001302. doi: 10.1097/JU.0000000000001302.
    PubMed     Abstract available


  159. WANG AZ, O'Connor LP, Yerram NK, Long L, et al
    PIRADS Category as a Predictor of Progression to Unfavorable Risk Prostate Cancer in Men on Active Surveillance.
    J Urol. 2020 Jul 27:101097JU0000000000001307. doi: 10.1097/JU.0000000000001307.
    PubMed     Abstract available


  160. TANEJA SS
    Re: Prostate-Specific Membrane Antigen PET-CT in Patients with High-Risk Prostate Cancer before Curative-Intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multicentre Study.
    J Urol. 2020 Jul 27:101097JU000000000000122001.
    PubMed    


  161. TANEJA SS
    Re: Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    J Urol. 2020 Jul 27:101097JU0000000000001220. doi: 10.1097/JU.0000000000001220.
    PubMed    


  162. TANEJA SS
    Re: Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men with Locally Advanced Prostate Cancer: 10-Year Data from the TROG 03.04 RADAR Trial.
    J Urol. 2020 Jul 27:101097JU000000000000122002.
    PubMed    


  163. ATALA A
    Re: OXPHOS Remodeling in High-Grade Prostate Cancer Involves mtDNA Mutations and Increased Succinate Oxidation.
    J Urol. 2020 Jul 24:101097JU0000000000001222. doi: 10.1097/JU.0000000000001222.
    PubMed    


  164. GRIEBLING TL
    Re: Home-Based 'Exergaming' Was Safe and Significantly Improved 6-Min Walking Distance in Patients with Prostate Cancer: A Single-Blinded Randomised Controlled Trial.
    J Urol. 2020 Jul 23:101097JU000000000000120703.
    PubMed    


  165. DENIFFEL D, Haider M, Perlis N
    Re: Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
    J Urol. 2020 Jul 23:101097JU0000000000001296. doi: 10.1097/JU.0000000000001296.
    PubMed    


  166. STAVRINIDES V, Giganti F, Punwani S, Allen C, et al
    Re: Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
    J Urol. 2020 Jul 23:101097JU0000000000001295. doi: 10.1097/JU.0000000000001295.
    PubMed    


  167. CARLSSON SV, Touijer K
    Re: Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with AS at a Tertiary Cancer Center.
    J Urol. 2020 Jul 23:101097JU0000000000001292. doi: 10.1097/JU.0000000000001292.
    PubMed    


  168. SHAH N, Ioffe V
    Re: Risk of metastasis in men with Grade Group 2 prostate cancer managed with active surveillance at a tertiary cancer center.
    J Urol. 2020 Jul 23:101097JU0000000000001291. doi: 10.1097/JU.0000000000001291.
    PubMed    


  169. AGRAWAL V, Ma X, Hu JC, Barbieri CE, et al
    Active Surveillance for Men with Intermediate Risk Prostate Cancer.
    J Urol. 2020 Jul 13:101097JU0000000000001241. doi: 10.1097/JU.0000000000001241.
    PubMed     Abstract available


  170. KINNAIRD A, Sharma V, Chuang R, Priester A, et al
    Risk of Prostate Cancer after a Negative MRI-Guided Biopsy.
    J Urol. 2020 Jul 2:101097JU0000000000001232. doi: 10.1097/JU.0000000000001232.
    PubMed     Abstract available


  171. MOSCHINI M, Rozet F
    Editorial Comment.
    J Urol. 2020;204:32.
    PubMed    


  172. KILPELAINEN T, Lahdensuo K, Rannikko A
    Editorial Comment.
    J Urol. 2020;204:32.
    PubMed    


  173. PAGNIEZ MA, Kasivisvanathan V, Puech P, Drumez E, et al
    Predictive Factors of Missed Clinically Significant Prostate Cancers in Men with Negative Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis.
    J Urol. 2020;204:24-32.
    PubMed     Abstract available


  174. TODENHOFER T
    Editorial Comment.
    J Urol. 2020;204:77.
    PubMed    


  175. SPRATT DE
    Editorial Comment.
    J Urol. 2020;204:89-90.
    PubMed    


  176. FALAGARIO UG, Ratnani P, Lantz A, Jambor I, et al
    Staging Accuracy of Multiparametric Magnetic Resonance Imaging in Caucasian and African American Men Undergoing Radical Prostatectomy.
    J Urol. 2020;204:82-90.
    PubMed     Abstract available


  177. SOETERIK TFW, van Melick HHE, Dijksman LM, Stomps S, et al
    Nerve Sparing during Robot-Assisted Radical Prostatectomy Increases the Risk of Ipsilateral Positive Surgical Margins.
    J Urol. 2020;204:91-95.
    PubMed     Abstract available


  178. CADEDDU JA
    Re: Comparison of Outcomes of Salvage Robot-Assisted Laparoscopic Prostatectomy for Post-Primary Radiation vs Focal Therapy.
    J Urol. 2020;204:168.
    PubMed    


  179. HAJIRAN A, Pow-Sang J
    Re: Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study.
    J Urol. 2020;204:159.
    PubMed    


  180. FULLER TW, Ballon-Landa E, Gallo K, Smith TG 3rd, et al
    Outcomes and Risk Factors of Revision and Replacement Artificial Urinary Sphincter Implantation in Radiated and Nonradiated Cases.
    J Urol. 2020;204:110-114.
    PubMed     Abstract available


    June 2020
  181. RESNICK MJ
    Re: Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression among Men with Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial.
    J Urol. 2020 Jun 26:101097JU0000000000001171. doi: 10.1097/JU.0000000000001171.
    PubMed    


  182. TANEJA SS
    Re: Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.
    J Urol. 2020 Jun 26:101097JU000000000000117601.
    PubMed    


  183. TANEJA SS
    Re: Validation of a Subclassification for High-Risk Prostate Cancer in a Prospective Cohort.
    J Urol. 2020 Jun 26:101097JU0000000000001176. doi: 10.1097/JU.0000000000001176.
    PubMed    


  184. TANEJA SS
    Re: Artificial Intelligence for Diagnosis and Grading of Prostate Cancer in Biopsies: A Population-Based, Diagnostic Study.
    J Urol. 2020 Jun 26:101097JU000000000000117602.
    PubMed    


  185. REISZ PA, Laviana AA, Zhao Z, Huang LC, et al
    Assessing the Quality of Surgical Care for Clinically Localized Prostate Cancer: Results from the CEASAR Study.
    J Urol. 2020 Jun 22:101097JU0000000000001198. doi: 10.1097/JU.0000000000001198.
    PubMed     Abstract available


  186. PARK KJ, Choi SH, Lee JS, Kim JK, et al
    Inter-reader Agreement in Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer: A Systematic Review and Meta-Analysis.
    J Urol. 2020 Jun 18:101097JU0000000000001200. doi: 10.1097/JU.0000000000001200.
    PubMed     Abstract available


  187. ATALA A
    Re: Long Noncoding RNA DRAIC Inhibits Prostate Cancer Progression by Interacting with IKK to Inhibit NF-kappaB Activation.
    J Urol. 2020 Jun 18:101097JU0000000000001179. doi: 10.1097/JU.0000000000001179.
    PubMed    


  188. LONERGAN PE, Washington SL 3rd, Cowan JE, Zhao S, et al
    Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer.
    J Urol. 2020 Jun 10:101097JU0000000000001186. doi: 10.1097/JU.0000000000001186.
    PubMed     Abstract available


  189. DENIFFEL D, Salinas E, Ientilucci M, Evans AJ, et al
    Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
    J Urol. 2020 Jun 4:101097JU0000000000001157. doi: 10.1097/JU.0000000000001157.
    PubMed     Abstract available


  190. O'NEIL B
    Editorial Comment.
    J Urol. 2020;203:1116.
    PubMed    


  191. CARROLL PR, Chu C
    Editorial Comment.
    J Urol. 2020;203:1121.
    PubMed    


  192. SAIDIAN A, Vishwanath V, Rais-Bahrami S
    Editorial Comment.
    J Urol. 2020;203:1092-1093.
    PubMed    


  193. KAOUK J, Aminsharifi A, Wilson CA, Sawczyn G, et al
    Extraperitoneal versus Transperitoneal Single Port Robotic Radical Prostatectomy: A Comparative Analysis of Perioperative Outcomes.
    J Urol. 2020;203:1135-1140.
    PubMed     Abstract available


  194. MOTTERLE G, Ahmed ME, Andrews JR, Moschini M, et al
    Tumor Seeding after Robot-Assisted Radical Prostatectomy: Literature Review and Experience from a Single Institution.
    J Urol. 2020;203:1141-1146.
    PubMed     Abstract available


    May 2020
  195. GIRI VN, Hyatt C, Leader A
    Cancer Screening and Genetic Testing Recommendations for Relatives of Men Undergoing Prostate Cancer Germline Testing: Implications for Practice.
    J Urol. 2020 May 27:101097JU0000000000001150. doi: 10.1097/JU.0000000000001150.
    PubMed    


  196. TANEJA SS
    Re: Influence of the Facility Caseload on the Subsequent Survival of Men with Localized Prostate Cancer Undergoing Radical Prostatectomy.
    J Urol. 2020 May 13:101097JU000000000000111502.
    PubMed    


  197. TANEJA SS
    Re: Utility of Multiparametric Magnetic Resonance Imaging in the Risk Stratification of Men with Grade Group 1 Prostate Cancer on Active Surveillance.
    J Urol. 2020 May 13:101097JU0000000000001115. doi: 10.1097/JU.0000000000001115.
    PubMed    


  198. TANEJA SS
    Re: Prostate Cancer Mortality and Metastasis under Different Biopsy Frequencies in North American Active Surveillance Cohorts.
    J Urol. 2020 May 13:101097JU000000000000111501.
    PubMed    


  199. GRIEBLING TL
    Re: Do Canadian Radiation Oncologists Consider Geriatric Assessment in the Decision-Making Process for Treatment of Patients 80 Years and Older with Non-Metastatic Prostate Cancer? National Survey.
    J Urol. 2020 May 13:101097JU000000000000110201.
    PubMed    


  200. GRIEBLING TL
    Re: Patients with Prostate Cancer and Androgen Deprivation Therapy Have Increased Risk of Fractures-A Study from the Fractures and Fall Injuries in the Elderly Cohort (FRAILCO).
    J Urol. 2020 May 13:101097JU000000000000110202.
    PubMed    


  201. GRIEBLING TL
    Re: Osteoporosis and Prostate Cancer; A 24-Month Prospective Observational Study during Androgen Deprivation Therapy.
    J Urol. 2020 May 13:101097JU000000000000110203.
    PubMed    


  202. GRIEBLING TL
    Re: Low-Value Prostate Cancer Screening among Older Men within the Veterans Health Administration.
    J Urol. 2020 May 13:101097JU0000000000001102. doi: 10.1097/JU.0000000000001102.
    PubMed    


  203. ATALA A
    Re: Galpha-13 Induces C X C Motif Chemokine Ligand 5 Expression in Prostate Cancer Cells by Transactivating NF-kappaB.
    J Urol. 2020 May 12:101097JU000000000000111702.
    PubMed    


  204. STOLZENBACH LF, Rosiello G, Deuker M, Colla-Ruvolo C, et al
    The Impact of Race and Age on Distribution of Metastases in Patients with Prostate Cancer.
    J Urol. 2020 May 12:101097JU0000000000001131. doi: 10.1097/JU.0000000000001131.
    PubMed     Abstract available


  205. CLAROS OR, Tourinho-Barbosa RR, Fregeville A, Gallardo AC, et al
    Re: Comparison of Initial Experience with Transrectal Magnetic Resonance Imaging Cognitive Guided Micro-Ultrasound Biopsies versus Established Transperineal Robotic Ultrasound Magnetic Resonance Imaging Fusion Biopsies for Prostate Cancer.
    J Urol. 2020 May 5:101097JU0000000000001123. doi: 10.1097/JU.0000000000001123.
    PubMed    


  206. MARKS LS, Natarajan S
    RE: Prostate Cancer Detection Rate of Free-hand versus 3D Template Mapping Biopsy Using an MRI/Ultrasound Fusion Device in Biopsy-Naive Men.
    J Urol. 2020 May 4:101097JU0000000000001124. doi: 10.1097/JU.0000000000001124.
    PubMed    


  207. GANDAGLIA G, Briganti A, Fossati N, Montorsi F, et al
    Re: Comparison of Initial Experience with Transrectal MRI Cognitive Guided Micro-ultrasound Biopsies versus Established Transperineal Robotic Ultrasound-Magnetic Resonance Imaging Fusion Biopsies for Prostate Cancer.
    J Urol. 2020 May 4:101097JU0000000000001122. doi: 10.1097/JU.0000000000001122.
    PubMed    


  208. SCHAEFFER EM
    Re: Multiparametric MRI Appearances of Primary Granulomatous Prostatitis.
    J Urol. 2020;203:862.
    PubMed    


  209. MARKS LS, Kinnaird A
    Editorial Comment.
    J Urol. 2020;203:924.
    PubMed    


  210. GHAI S
    Editorial Comment.
    J Urol. 2020;203:923-924.
    PubMed    


  211. SCHAEFFER EM
    Re: Sustained Influence of Infections on Prostate-Specific Antigen Concentration: An Analysis of Changes over 10 Years of Follow-up.
    J Urol. 2020;203:861-862.
    PubMed    


  212. JONES JS
    Editorial Comment.
    J Urol. 2020;203:938-939.
    PubMed    


  213. XIA L, Sperling CD, Taylor BL, Talwar R, et al
    Associations between Hospital Volume and Outcomes of Robot-Assisted Radical Prostatectomy.
    J Urol. 2020;203:926-932.
    PubMed     Abstract available


  214. POULIOT F, Rouleau M, Neveu B, Toren P, et al
    Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy.
    J Urol. 2020;203:940-948.
    PubMed     Abstract available


  215. AMIN A, Scheltema MJ, Shnier R, Blazevski A, et al
    The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies.
    J Urol. 2020;203:910-917.
    PubMed     Abstract available


    April 2020
  216. ALEMOZAFFAR M, Akintayo AA, Abiodun-Ojo OA, Patil D, et al
    [(18)F]fluciclovine PET/CT for Preoperative Staging in Patients with Intermediate to High-Risk Primary Prostate Cancer.
    J Urol. 2020 Apr 29:101097JU0000000000001095. doi: 10.1097/JU.0000000000001095.
    PubMed     Abstract available


  217. DETSKY JS, Ghiam AF, Mamedov A, Commisso K, et al
    Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer.
    J Urol. 2020 Apr 24:101097JU0000000000001091. doi: 10.1097/JU.0000000000001091.
    PubMed     Abstract available


  218. TANEJA SS
    Re: Lifetime Benefits and Harms of PSA-Based Risk Screening for Prostate Cancer.
    J Urol. 2020 Apr 15:101097JU000000000000105602.
    PubMed    


  219. TANEJA SS
    Re: Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression among Men with Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial.
    J Urol. 2020 Apr 15:101097JU0000000000001056. doi: 10.1097/JU.0000000000001056.
    PubMed    


  220. TANEJA SS
    Re: Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT).
    J Urol. 2020 Apr 15:101097JU000000000000105601.
    PubMed    


  221. MONTORSI F, Fossati N, Gandaglia G, Briganti A, et al
    (68)Ga-PSMA-PET/CT Scan as Primary Staging for Prostate Cancer and Its Related Clinical Implications.
    J Urol. 2020 Apr 13:101097JU0000000000001081. doi: 10.1097/JU.0000000000001081.
    PubMed    


  222. ATALA A
    Re: miR-191 Promotes Radiation Resistance of Prostate Cancer through Interaction with RXRA.
    J Urol. 2020 Apr 9:101097JU000000000000105801.
    PubMed    


  223. RANASINGHE W, Reichard CA, Nyame YA, Sundi D, et al
    Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer.
    J Urol. 2020 Apr 7:101097JU0000000000001074. doi: 10.1097/JU.0000000000001074.
    PubMed     Abstract available


  224. WOO J, Santasusagna S, Banks J, Pastor-Lopez S, et al
    Urine Extracellular Vesicle GATA2 mRNA Discriminates Biopsy Result in Men with Suspicion of Prostate Cancer.
    J Urol. 2020 Apr 6:101097JU0000000000001066. doi: 10.1097/JU.0000000000001066.
    PubMed     Abstract available


  225. MARKOWSKI MC, Sedhom R, Fu W, Gray JCR, et al
    PSA and PSA Doubling Time Predict Findings on (18)F-DCFPyL PET/CT in Patients with Biochemically-Recurrent Prostate Cancer.
    J Urol. 2020 Apr 6:101097JU0000000000001064. doi: 10.1097/JU.0000000000001064.
    PubMed     Abstract available


  226. BONDE MIRANDA T, Garmo H, Stattin P, Robinson D, et al
    5alpha-Reductase Inhibitors and Risk of Prostate Cancer Death.
    J Urol. 2020 Apr 3:101097JU0000000000001038. doi: 10.1097/JU.0000000000001038.
    PubMed     Abstract available


  227. TOSOIAN JJ
    Editorial Comment.
    J Urol. 2020;203:732.
    PubMed    


  228. KLAASSEN Z, Wallis CJD
    Editorial Comment.
    J Urol. 2020;203:758-759.
    PubMed    


  229. STEYERBERG EW
    Editorial Comment.
    J Urol. 2020;203:726.
    PubMed    


  230. MEHRALIVAND S
    Editorial Comment.
    J Urol. 2020;203:725-726.
    PubMed    


  231. LEAPMAN M
    Editorial Comment.
    J Urol. 2020;203:705.
    PubMed    


  232. NELSON M, Dornbier R, Kirshenbaum E, Eguia E, et al
    Use of Surgery for Post-Prostatectomy Incontinence.
    J Urol. 2020;203:786-791.
    PubMed     Abstract available


    March 2020
  233. WANG WW, Sorokin I, Aleksic I, Mian B, et al
    Expression of Small Non-coding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease.
    J Urol. 2020 Mar 19:101097JU0000000000001020. doi: 10.1097/JU.0000000000001020.
    PubMed     Abstract available


  234. HALSTUCH D, Ber Y, Kedar D, Golan S, et al
    Short-Term Outcomes of Active Surveillance for Low-Risk Prostate Cancer Among Men with Germline DNA Repair Gene Mutations.
    J Urol. 2020 Mar 19:101097JU0000000000001027. doi: 10.1097/JU.0000000000001027.
    PubMed     Abstract available


  235. TANEJA SS
    Re: Statin Use is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer.
    J Urol. 2020 Mar 18:101097JU0000000000001000. doi: 10.1097/JU.0000000000001000.
    PubMed    


  236. NAHAR B, Bhat A, Reis IM, Soodana-Prakash N, et al
    Prospective Evaluation of Focal High-Intensity Focused Ultrasound (HIFU) for Patients with Localized Prostate Cancer.
    J Urol. 2020 Mar 13:101097JU0000000000001015. doi: 10.1097/JU.0000000000001015.
    PubMed     Abstract available


  237. MARRA G, Moschini M, Cathelineau X, Sanchez-Salas R, et al
    Re: Hemigland Cryoablation of Localized Low-, Intermediate- and High-Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years.
    J Urol. 2020 Mar 6:101097JU0000000000001008. doi: 10.1097/JU.0000000000001008.
    PubMed    


  238. ABREU AL, Oishi M, Tafuri A, Shakir A, et al
    RE: Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years.
    J Urol. 2020 Mar 6:101097JU0000000000001009. doi: 10.1097/JU.0000000000001009.
    PubMed    


  239. VERTOSICK EA, Haggstrom C, Sjoberg DD, Hallmans G, et al
    Prespecified Four Kallikrein Marker Model (4Kscore) at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population-Based Cohort of Asymptomatic Men Followed for 20 Years.
    J Urol. 2020 Mar 3:101097JU0000000000001007. doi: 10.1097/JU.0000000000001007.
    PubMed     Abstract available


  240. IRAVANI A
    Editorial Comment.
    J Urol. 2020;203:544-545.
    PubMed    


  241. SIEGEL C
    Re: A Review of the Principles of Texture Analysis and its Role in Imaging of Genitourinary Neoplasms.
    J Urol. 2020;203:444.
    PubMed    


  242. BAUNACKE M, Schmidt ML, Groeben C, Borkowetz A, et al
    Decision Regret after Radical Prostatectomy does Not Depend on Surgical Approach: 6-Year Followup of a Large German Cohort Undergoing Routine Care.
    J Urol. 2020;203:554-561.
    PubMed     Abstract available


  243. GROSS MD, Marks LS, Sonn GA, Green DA, et al
    Variation in Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy Outcomes in Asian American Men: A Multicenter Study.
    J Urol. 2020;203:530-536.
    PubMed     Abstract available


  244. CHAPPIDI MR, Stimson CJ, Kates M, Odisho AY, et al
    A Nationally Representative Study of Nonindex Hospital Readmissions following Radical Prostatectomy: Implications for Bundled Payment Models.
    J Urol. 2020;203:546-553.
    PubMed     Abstract available


    February 2020
  245. SAAD F, Fleshner N, Pickles T, Niazi T, et al
    Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer.
    J Urol. 2020 Feb 25:101097JU0000000000000809. doi: 10.1097/JU.0000000000000809.
    PubMed     Abstract available


  246. OAKE JD, Shiff B, Harasemiw O, Tangri N, et al
    The Comparative Outcomes of Radical Prostatectomy versus Radiotherapy for Non-metastatic Prostate Cancer: A Longitudinal, Population-Based Analysis.
    J Urol. 2020 Feb 18:101097JU0000000000000805. doi: 10.1097/JU.0000000000000805.
    PubMed     Abstract available


  247. INABA H, Kimura T, Onuma H, Sato S, et al
    Tumor Location and Pathological Features of Latent and Incidental Prostate Cancer in Contemporary Japanese Men.
    J Urol. 2020 Feb 18:101097JU0000000000000804. doi: 10.1097/JU.0000000000000804.
    PubMed     Abstract available


  248. STUOPELYTE K, Sabaliauskaite R, Bakavicius A, Haflidadottir BS, et al
    Analysis of AR-FL and AR-V1 in Whole Blood of Patients with Castration Resistant Prostate Cancer as a Tool for Predicting Response to Abiraterone Acetate.
    J Urol. 2020 Feb 18:101097JU0000000000000803. doi: 10.1097/JU.0000000000000803.
    PubMed     Abstract available


  249. FOSSATI N, Scarcella S, Gandaglia G, Suardi N, et al
    Underestimation of PET/CT Scan in Assessing Tumour Burden of Men With Nodal Recurrence From Prostate Cancer: Head-to-Head Comparison OF (68)Ga-PSMA and (11)C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections.
    J Urol. 2020 Feb 18:101097JU0000000000000800. doi: 10.1097/JU.0000000000000800.
    PubMed     Abstract available


  250. KAPLAN SA
    Re: Impact of 5alpha-Reductase Inhibitor and alpha-Blocker Therapy for Benign Prostatic Hyperplasia on Prostate Cancer Incidence and Mortality.
    J Urol. 2020 Feb 13:101097JU000000000000076302.
    PubMed    


  251. TANEJA SS
    Re: Ten-Year Mortality, Disease Progression, and Treatment-Related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.
    J Urol. 2020 Feb 13:101097JU000000000000077902.
    PubMed    


  252. TANEJA SS
    Re: Long Term Follow-up and Outcomes of Re-Treatment in an Expanded 50 Patient Single-Center Phase II Prospective Trial of Lutetium-177 ((177)Lu) PSMA-617 Theranostics in Metastatic Castrate-Resistant Prostate Cancer.
    J Urol. 2020 Feb 13:101097JU000000000000077901.
    PubMed    


  253. TANEJA SS
    Re: Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive: The Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) Study.
    J Urol. 2020 Feb 13:101097JU0000000000000779. doi: 10.1097/JU.0000000000000779.
    PubMed    


  254. ATALA A
    Re: High-Fat Diet Fuels Prostate Cancer Progression by Rewiring the Metabolome and Amplifying the MYC Program.
    J Urol. 2020 Feb 12:101097JU000000000000078102.
    PubMed    


  255. SIEGEL C
    Re: Diagnostic Value of CT in Detecting Peripheral Zone Prostate Cancer.
    J Urol. 2020 Feb 10:101097JU0000000000000766. doi: 10.1097/JU.0000000000000766.
    PubMed    


  256. SATKUNASIVAM R, Miles BJ
    Editorial Comment.
    J Urol. 2020;203:329.
    PubMed    


  257. PERLIS N
    Editorial Comment.
    J Urol. 2020;203:329.
    PubMed    


  258. TANEJA SS
    Re: Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium.
    J Urol. 2020;203:252-253.
    PubMed    


  259. CADEDDU JA
    Re: Robot-Assisted Radical Prostatectomy after Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence.
    J Urol. 2020;203:233.
    PubMed    


  260. HANEY NM, Faisal FA, Lu J, Guedes LB, et al
    PTEN Loss with ERG Negative Status is Associated with Lethal Disease after Radical Prostatectomy.
    J Urol. 2020;203:344-350.
    PubMed     Abstract available


  261. ABEDALI ZA, Calaway AC, Large T, Lingeman JE, et al
    The Role of Prostate Specific Antigen Monitoring after Holmium Laser Enucleation of the Prostate.
    J Urol. 2020;203:304-310.
    PubMed     Abstract available


  262. ERICSON KJ, Wu SS, Lundy SD, Thomas LJ, et al
    Diagnostic Accuracy of Prostate Biopsy for Detecting Cribriform Gleason Pattern 4 Carcinoma and Intraductal Carcinoma in Paired Radical Prostatectomy Specimens: Implications for Active Surveillance.
    J Urol. 2020;203:311-319.
    PubMed     Abstract available


  263. ZHAO H, Howard LE, De Hoedt A, Terris MK, et al
    Racial Discrepancies in Overall Survival among Men Treated with (223)Radium.
    J Urol. 2020;203:331-337.
    PubMed     Abstract available


  264. DENIFFEL D, Zhang Y, Salinas E, Satkunasivam R, et al
    Reducing Unnecessary Prostate Multiparametric Magnetic Resonance Imaging by Using Clinical Parameters to Predict Negative and Indeterminate Findings.
    J Urol. 2020;203:292-298.
    PubMed     Abstract available


  265. PREISSER F, van den Bergh RCN, Gandaglia G, Ost P, et al
    Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study.
    J Urol. 2020;203:338-343.
    PubMed     Abstract available


  266. ALDER R, Zetner D, Rosenberg J
    Incidence of Inguinal Hernia after Radical Prostatectomy: A Systematic Review and Meta-Analysis.
    J Urol. 2020;203:265-274.
    PubMed     Abstract available


    January 2020
  267. JANSSON F, Folkvaljon F, Stattin P, Bratt O, et al
    Risk of Postoperative Upstaging or Upgrading Among Men with Low-Risk Familial Prostate Cancer.
    J Urol. 2020 Jan 31:101097JU0000000000000793. doi: 10.1097/JU.0000000000000793.
    PubMed     Abstract available


  268. LOUGHLIN KR
    Re: Undertreatment of Prostate Cancer in Rural Locations.
    J Urol. 2020 Jan 27:101097JU0000000000000759. doi: 10.1097/JU.0000000000000759.
    PubMed    


  269. WATSON V, McCartan N, Krucien N, Abu V, et al
    Evaluating the Trade-offs Men with Localised Prostate Cancer Make Between the Risks and Benefits of Treatments: The COMPARE Study.
    J Urol. 2020 Jan 22:101097JU0000000000000754. doi: 10.1097/JU.0000000000000754.
    PubMed     Abstract available


  270. ATALA A
    Re: Selective Targeting of PARP-2 Inhibits Androgen Receptor Signaling and Prostate Cancer Growth through Disruption of FOXA1 Function.
    J Urol. 2020 Jan 13:101097JU0000000000000732. doi: 10.1097/JU.0000000000000732.
    PubMed    


  271. ATALA A
    Re: The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression.
    J Urol. 2020 Jan 13:101097JU000000000000073201.
    PubMed    


  272. TANEJA SS
    Re: Risk of Prostate Cancer for Men Fathering through Assisted Reproduction: Nationwide Population Based Register Study.
    J Urol. 2020 Jan 13:101097JU000000000000073002.
    PubMed    


  273. TANEJA SS
    Re: Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
    J Urol. 2020 Jan 13:101097JU000000000000073001.
    PubMed    


  274. ELLIOTT S
    Re: Salvage Brachytherapy for Locally-Recurrent Prostate Cancer after Radiation Therapy: A Comparison of Efficacy and Toxicity Outcomes with High-Dose Rate and Low-Dose Rate Brachytherapy.
    J Urol. 2020 Jan 13:101097JU000000000000074501.
    PubMed    


  275. HUBER PM, Afzal N, Arya M, Boxler S, et al
    PSA Criteria to Diagnose Failure of Cancer Control following Focal Therapy for Non-metastatic Prostate Cancer Using High Intensity Focused Ultrasound.
    J Urol. 2020 Jan 13:101097JU0000000000000747. doi: 10.1097/JU.0000000000000747.
    PubMed     Abstract available


  276. CARLSSON S, Benfante N, Alvim R, Sjoberg DD, et al
    Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center.
    J Urol. 2020 Jan 7:101097JU0000000000000742. doi: 10.1097/JU.0000000000000742.
    PubMed     Abstract available


  277. LEONG DP, Fradet V, Shayegan B, Duceppe E, et al
    Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study.
    J Urol. 2020 Jan 3:101097JU0000000000000714. doi: 10.1097/JU.0000000000000714.
    PubMed     Abstract available


  278. TANEJA SS
    Re: Gold Nanoshell-Localized Photothermal Ablation of Prostate Tumors in a Clinical Pilot Device Study.
    J Urol. 2020;203:31.
    PubMed    


  279. EMMETT L, Hofman MS
    Editorial Comment.
    J Urol. 2020;203:99.
    PubMed    


  280. HAMILTON RJ
    Editorial Comment.
    J Urol. 2020;203:126-127.
    PubMed    


  281. LOEB S, Cazzaniga W, Robinson D, Garmo H, et al
    Opioid Use after Radical Prostatectomy: Nationwide, Population Based Study in Sweden.
    J Urol. 2020;203:145-150.
    PubMed     Abstract available


  282. FILSON CP
    Editorial Comment.
    J Urol. 2020;203:135.
    PubMed    


  283. ZAMBRANO IA, Tan HJ
    Editorial Comment.
    J Urol. 2020;203:135-136.
    PubMed    


  284. TODENHOFER T
    Editorial Comment.
    J Urol. 2020;203:81.
    PubMed    


  285. XU J, Helfand BT
    Editorial Comment.
    J Urol. 2020;203:80-81.
    PubMed    


  286. LEE J, Kim HY, Goh HJ, Heo JE, et al
    Retzius Sparing Robot-Assisted Radical Prostatectomy Conveys Early Regain of Continence over Conventional Robot-Assisted Radical Prostatectomy: A Propensity Score Matched Analysis of 1,863 Patients.
    J Urol. 2020;203:137-144.
    PubMed     Abstract available


  287. LOVEGROVE CE, Miah S, El-Shater Bosaily A, Bott S, et al
    Comparison of Transrectal Ultrasound Biopsy to Transperineal Template Mapping Biopsies Stratified by Multiparametric Magnetic Resonance Imaging Score in the PROMIS Trial.
    J Urol. 2020;203:100-107.
    PubMed     Abstract available


    December 2019
  288. CARLSSON S, Benfante N, Alvim R, Sjoberg DD, et al
    Long-Term Outcomes of Active Surveillance for Prostate Cancer - The Memorial Sloan Kettering Cancer Center Experience.
    J Urol. 2019 Dec 23:101097JU0000000000000713. doi: 10.1097/JU.0000000000000713.
    PubMed     Abstract available


  289. PAK S, Suh YS, Lee DE, Kim SH, et al
    Association Between Postoperative Detection of Circulating Tumor Cells and Recurrence in Patients with Prostate Cancer.
    J Urol. 2019 Dec 17:101097JU0000000000000704. doi: 10.1097/JU.0000000000000704.
    PubMed     Abstract available


  290. SHAH N, Ioffe V
    Re: Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication.
    J Urol. 2019 Dec 17:101097JU0000000000000702. doi: 10.1097/JU.0000000000000702.
    PubMed    


  291. GULATI R, Etzioni R
    Re: Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication.
    J Urol. 2019 Dec 17:101097JU0000000000000703. doi: 10.1097/JU.0000000000000703.
    PubMed    


  292. TANEJA SS
    Re: Metastasis-Directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-Institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.
    J Urol. 2019 Dec 12:101097JU000000000000067701.
    PubMed    


  293. TANEJA SS
    Re: Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.
    J Urol. 2019 Dec 12:101097JU000000000000067702.
    PubMed    


  294. TANEJA SS
    Re: Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de Novo Low AR-Active Subclass in Treatment Naive Primary Prostate Cancer.
    J Urol. 2019 Dec 12:101097JU0000000000000677. doi: 10.1097/JU.0000000000000677.
    PubMed    


  295. GRIEBLING TL
    Re: Gay Men's Experiences of Sexual Changes after Prostate Cancer Treatment-A Qualitative Study in Sweden.
    J Urol. 2019 Dec 12:101097JU000000000000066404.
    PubMed    


  296. CLAROS OR, Tourinho-Barbosa RR, Fregeville A, Gallardo AC, et al
    Comparison of Initial Experience with Transrectal MRI Cognitive Guided Micro-ultrasound Biopsies versus Established Transperineal Robotic Ultrasound-Magnetic Resonance Imaging Fusion Biopsies for Prostate Cancer.
    J Urol. 2019 Dec 10:101097JU0000000000000692. doi: 10.1097/JU.0000000000000692.
    PubMed     Abstract available


  297. ATALA A
    Re: Betaglycan Drives the Mesenchymal Stromal Cell Osteogenic Program and Prostate Cancer-Induced Osteogenesis.
    J Urol. 2019 Dec 3:101097JU0000000000000679. doi: 10.1097/JU.0000000000000679.
    PubMed    


  298. ATALA A
    Re: The Androgen Receptor Regulates a Druggable Translational Regulon in Advanced Prostate Cancer.
    J Urol. 2019 Dec 3:101097JU000000000000067901.
    PubMed    


  299. FAROLFI A, Gafita A, Calais J, Eiber M, et al
    Reply by Authors.
    J Urol. 2019;202:1181.
    PubMed    


  300. OISHI M, Gill IS, Tafuri A, Shakir A, et al
    Reply by Authors.
    J Urol. 2019;202:1198.
    PubMed    


  301. KAPOOR J, Koschel S, Murphy DG
    Editorial Comment.
    J Urol. 2019;202:1180-1181.
    PubMed    


  302. CHIN JL
    Editorial Comment.
    J Urol. 2019;202:1197-1198.
    PubMed    


  303. SCATTONI V
    Editorial Comment.
    J Urol. 2019;202:1172.
    PubMed    


  304. MANNAERTS CK, Wildeboer RR, Remmers S, van Kollenburg RAA, et al
    Reply by Authors.
    J Urol. 2019;202:1172-1173.
    PubMed    


  305. ALCARAZ KI
    Editorial Comment.
    J Urol. 2019;202:1215-1216.
    PubMed    


  306. KILPELAINEN TP, Jarvinen P, Tikkinen KAO
    Randomized Trials Show a Consistent Benefit of Radical Prostatectomy on Mortality Outcomes.
    J Urol. 2019;202:1106-1108.
    PubMed    


  307. PLOUSSARD G, Beauval JB, Lesourd M, Almeras C, et al
    Added Value of Concomitant Systematic and Fusion Targeted Biopsies for Grade Group Prediction Based on Radical Prostatectomy Final Pathology on Positive Magnetic Resonance Imaging.
    J Urol. 2019;202:1182-1187.
    PubMed     Abstract available


  308. LO G, Burton KR, Haider MA, Fleshner N, et al
    Negative Predictive Value of Prostate Multiparametric Magnetic Resonance Imaging among Men with Negative Prostate Biopsy and Elevated Prostate Specific Antigen: A Clinical Outcome Retrospective Cohort Study.
    J Urol. 2019;202:1159-1165.
    PubMed     Abstract available


  309. AL HUSSEIN AL AWAMLH B, Shoag JE, Ravikumar V, Posada L, et al
    Association of Smoking and Death from Genitourinary Malignancies: Analysis of the National Longitudinal Mortality Study.
    J Urol. 2019;202:1248-1254.
    PubMed     Abstract available


    November 2019
  310. WEINER AB, Cohen JE, DeLancey JO, Schaeffer EM, et al
    Surgical Versus Medical Castration for Metastatic Prostate Cancer: Use and Overall Survival in a National Cohort.
    J Urol. 2019 Nov 20:101097JU0000000000000684. doi: 10.1097/JU.0000000000000684.
    PubMed     Abstract available


  311. DRAULANS C, Everaerts W, Isebaert S, Van Bruwaene S, et al
    Development and External Validation of a mpMRI- and ISUP-Based Add-on Prediction Tool to Identity Prostate Cancer Candidates for Pelvic Lymph Node Dissection.
    J Urol. 2019 Nov 13:101097JU0000000000000652. doi: 10.1097/JU.0000000000000652.
    PubMed     Abstract available


  312. GRIEBLING TL
    Re: Effect of Androgen Deprivation Therapy on Other-Cause of Mortality in Elderly Patients with Clinically Localized Prostate Cancer Treated with Modern Radiotherapy: Is There a Negative Impact?
    J Urol. 2019 Nov 11:10109701JU000061471212731.
    PubMed    


  313. TANEJA SS
    Re: Oncological and Quality-of-Life Outcomes following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-Monitored Prospective Cohort.
    J Urol. 2019 Nov 11:10109701JU000061489640156.
    PubMed    


  314. TANEJA SS
    Re: Diagnostic Accuracy of Multiparametric MRI versus 68Ga-PSMA-11 PET/MRI for Extracapsular Extension and Seminal Vesicle Invasion in Patients with Prostate Cancer.
    J Urol. 2019 Nov 11:10109701JU000061489258082.
    PubMed    


  315. GRIEBLING TL
    Re: How to Choose Proper Local Treatment in Men Aged >/=75 Years with cT2 Localized Prostate Cancer?
    J Urol. 2019 Nov 11:10109701JU0000614720060019.
    PubMed    


  316. GRIEBLING TL
    Re: Intensity-Modulated Radiation Therapy for Elderly Patients (Aged >/=75 Years) with Localized Prostate Cancer: Comparison with Younger Patients (Aged <75 Years).
    J Urol. 2019 Nov 11:101097JU0000000000000639. doi: 10.1097/JU.0000000000000639.
    PubMed    


  317. GRIEBLING TL
    Re: Safety and Outcomes of New Generation Hormone-Therapy in Elderly Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Patients in the Real World.
    J Urol. 2019 Nov 11:10109701JU00006147169837619.
    PubMed    


  318. GRIEBLING TL
    Re: Risk of Cardiovascular Events in Men Treated for Prostate Cancer Compared with Prostate Cancer-Free Men.
    J Urol. 2019 Nov 9:10109701JU00006147248807477.
    PubMed    


  319. MARCHIONI M, Di Nicola M, Primiceri G, Novara G, et al
    New Anti-Androgen Compounds Compared to Docetaxel in Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis.
    J Urol. 2019 Nov 5:101097JU0000000000000636. doi: 10.1097/JU.0000000000000636.
    PubMed     Abstract available


  320. ATALA A
    Re: Dysregulation of p53-RBM25-Mediated circAMOTL1L Biogenesis Contributes to Prostate Cancer Progression through the circAMOTL1L-miR-193a-5p-Pcdha Pathway.
    J Urol. 2019 Nov 4:10109701JU0000613432221690.
    PubMed    


  321. PENSON DF
    Editorial Comment.
    J Urol. 2019;202:972.
    PubMed    


  322. WANG S, Siddiqui MM
    Editorial Comment.
    J Urol. 2019;202:951.
    PubMed    


  323. EGGENER S
    Editorial Comment.
    J Urol. 2019;202:942-943.
    PubMed    


  324. GHAI S
    Editorial Comment.
    J Urol. 2019;202:957.
    PubMed    


  325. JONES JS
    Editorial Comment.
    J Urol. 2019;202:957-958.
    PubMed    


  326. GROSS MD, Sedrakyan A, Bianco FJ, Carroll PR, et al
    Reply by Authors.
    J Urol. 2019;202:958.
    PubMed    


  327. GULATI R, Psutka SP, Etzioni R
    Reply by Authors.
    J Urol. 2019;202:943.
    PubMed    


    October 2019
  328. SABA K, Wettstein MS, Lieger L, Hotker AM, et al
    External Validation and Comparison of Prostate Cancer Risk Calculators Incorporating Multiparametric Magnetic Resonance Imaging for Prediction of Clinically Significant Prostate Cancer.
    J Urol. 2019 Oct 25:101097JU0000000000000622. doi: 10.1097/JU.0000000000000622.
    PubMed     Abstract available


  329. SCHENK JM, Newcomb LF, Zheng Y, Faino AV, et al
    African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study (PASS).
    J Urol. 2019 Oct 25:101097JU0000000000000621. doi: 10.1097/JU.0000000000000621.
    PubMed     Abstract available


  330. BJURLIN MA, Carroll PR, Eggener S, Fulgham PF, et al
    Update of the AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer.
    J Urol. 2019 Oct 23:101097JU0000000000000617. doi: 10.1097/JU.0000000000000617.
    PubMed     Abstract available


  331. RESNICK MJ
    Re: Urologist Practice Structure and Spending for Prostate Cancer Care.
    J Urol. 2019 Oct 21:10109701JU0000611480517223.
    PubMed    


  332. TANEJA SS
    Re: Ultra-Hypofractionated versus Conventionally Fractionated Radiotherapy for Prostate Cancer: 5-Year Outcomes of the HYPO-RT-PC Randomised, Non-Inferiority, Phase 3 Trial.
    J Urol. 2019 Oct 21:10109701JU000061150033954.
    PubMed    


  333. TANEJA SS
    Re: Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
    J Urol. 2019 Oct 21:10109701JU000061150441578.
    PubMed    


  334. GRIEBLING TL
    Re: Sarcopenia is a Poor Prognostic Factor of Castration-Resistant Prostate Cancer Treated with Docetaxel Therapy.
    J Urol. 2019 Oct 17:10109701JU0000604840216814.
    PubMed    


  335. ATALA A
    Re: Distinct Structural Classes of Activating FOXA1 Alterations in Advanced Prostate Cancer.
    J Urol. 2019 Oct 16:10109701JU00006047967711890.
    PubMed    


  336. GOLDBERG H, Ahmad AE, Chandrasekar T, Klotz L, et al
    Comparison of MRI- and TRUS-Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy-Naive Men: A Systematic Review and Meta-Analysis.
    J Urol. 2019 Oct 14:101097JU0000000000000595. doi: 10.1097/JU.0000000000000595.
    PubMed     Abstract available


  337. ZHOU SR, Chang E, Patankar A, Huang J, et al
    Prostate Cancer Detection Rate of Free-hand versus 3D Template Mapping Biopsy Using an MRI/Ultrasound Fusion Device in Biopsy-Naive Men.
    J Urol. 2019 Oct 9:101097JU0000000000000587. doi: 10.1097/JU.0000000000000587.
    PubMed     Abstract available


  338. DASKIVICH TJ, Thomas IC, Leppert JT
    Reply to Letter to the Editor Re: External Validation of the Prostate Cancer-specific Comorbidity Index (PCCI), a Claims-Based Tool for Prediction of Life Expectancy in Men with Prostate Cancer.
    J Urol. 2019 Oct 9:101097JU0000000000000586. doi: 10.1097/JU.0000000000000586.
    PubMed    


  339. FROEHNER M, Koch R, Thomas C
    Life Expectancy in Men with Prostate Cancer.
    J Urol. 2019 Oct 9:101097JU0000000000000585. doi: 10.1097/JU.0000000000000585.
    PubMed    


  340. CRAWFORD ED, Twardowski PW, Concepcion RS, Hafron JM, et al
    The Impact of Late LHRH Agonist Dosing on Testosterone Suppression in Prostate Cancer Patients: An Analysis of US Clinical Data.
    J Urol. 2019 Oct 3:101097JU0000000000000577. doi: 10.1097/JU.0000000000000577.
    PubMed     Abstract available


  341. KAPLAN SA
    Re: Serum Cholesterol and Risk of Lower Urinary Tract Symptoms Progression: Results from the Reduction by Dutasteride of Prostate Cancer Events Study.
    J Urol. 2019;202:635.
    PubMed    


  342. MURRAY NP
    Editorial Comment.
    J Urol. 2019;202:740-741.
    PubMed    


  343. EGGER S
    Editorial Comment.
    J Urol. 2019;202:695.
    PubMed    


  344. TANEJA SS
    Re: Evaluation of Intense Androgen Deprivation before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide with or without Abiraterone.
    J Urol. 2019;202:662.
    PubMed    


  345. PEDERZOLI F, Bandini M
    Editorial Comment.
    J Urol. 2019;202:716.
    PubMed    


  346. MONTIRONI R, Scarpelli M
    Editorial Comment.
    J Urol. 2019;202:715-716.
    PubMed    


  347. KLEIN EA
    Editorial Comment.
    J Urol. 2019;202:701.
    PubMed    


  348. KORNBERG Z, Cooperberg MR, Cowan JE, Chan JM, et al
    A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
    J Urol. 2019;202:702-709.
    PubMed     Abstract available


    September 2019
  349. TANEJA SS
    Re: Genomic Correlates of Clinical Outcome in Advanced Prostate Cancer.
    J Urol. 2019 Sep 18:10109701JU0000585744961900.
    PubMed    


  350. TANEJA SS
    Re: Alcohol Intake and Risk of Lethal Prostate Cancer in the Health Professionals Follow-Up Study.
    J Urol. 2019 Sep 18:10109701JU000058574803815.
    PubMed    


  351. RESNICK MJ
    Re: Self-Management in Long-Term Prostate Cancer Survivors: A Randomized, Controlled Trial.
    J Urol. 2019 Sep 13:101097JU0000000000000550. doi: 10.1097/JU.0000000000000550.
    PubMed    


  352. ATALA A
    Re: Communication of Prostate Cancer Cells with Bone Cells via Extracellular Vesicle RNA; a Potential Mechanism of Metastasis.
    J Urol. 2019 Sep 12:10109701JU0000585156807772.
    PubMed    


  353. WEINSTOCK C, Suzman D, Kluetz P, Baxley J, et al
    Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: FDA Oncology Center of Excellence Public Workshop.
    J Urol. 2019 Sep 10:101097JU0000000000000532. doi: 10.1097/JU.0000000000000532.
    PubMed     Abstract available


  354. VAN KALMTHOUT LWM, van Melick HHE, Lavalaye J, Meijer RP, et al
    Prospective Validation of Gallium-68 PSMA-PET/CT in Primary Staging of Prostate Cancer Patients.
    J Urol. 2019 Sep 5:101097JU0000000000000531. doi: 10.1097/JU.0000000000000531.
    PubMed     Abstract available


  355. LEYH-BANNURAH SR, Kachanov M, Beyersdorff D, Tian Z, et al
    Minimum Number of MRI Ultrasound Fusion Targeted Biopsy Cores Needed for Prostate Cancer Detection: Multivariable Retrospective Lesion-Based Analyses of Patients Treated with Radical Prostatectomy.
    J Urol. 2019 Sep 4:101097JU0000000000000527. doi: 10.1097/JU.0000000000000527.
    PubMed     Abstract available


  356. PAK S, Park SY, Shin TJ, You D, et al
    Reply by Authors.
    J Urol. 2019;202:531-532.
    PubMed    


  357. O'NEILL M, Alibhai SMH
    Editorial Comment.
    J Urol. 2019;202:530-531.
    PubMed    


  358. KARAKIEWICZ PI
    Editorial Comment.
    J Urol. 2019;202:531.
    PubMed    


  359. GORE JL
    Editorial Comment.
    J Urol. 2019;202:524.
    PubMed    


  360. STOYANOVA R
    Editorial Comment.
    J Urol. 2019;202:505.
    PubMed    


  361. NAYAN M, Fleshner N, Bozzo A
    Editorial Comment.
    J Urol. 2019;202:504-505.
    PubMed    


  362. PISANSKY TM, Thompson IM, Valicenti RK, D'Amico AV, et al
    Adjuvant and Salvage Radiotherapy after Prostatectomy: ASTRO/AUA Guideline Amendment 2018-2019.
    J Urol. 2019;202:533-538.
    PubMed     Abstract available


  363. VECCIA A, Antonelli A, Francavilla S, Porpiglia F, et al
    Minimally Invasive Radical Prostatectomy after Previous Bladder Outlet Surgery: A Systematic Review and Pooled Analysis of Comparative Studies.
    J Urol. 2019;202:511-517.
    PubMed     Abstract available


  364. BALAKRISHNAN AS, Cowan JE, Cooperberg MR, Shinohara K, et al
    Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance.
    J Urol. 2019;202:506-510.
    PubMed     Abstract available


    August 2019
  365. TOURINHO-BARBOSA RR, Sanchez-Salas R, Claros OR, Collura-Merlier S, et al
    Focal Therapy for Localized Prostate Cancer with Either HIFU or Cryoablation: A Single Institution Experience.
    J Urol. 2019 Aug 22:101097JU0000000000000506. doi: 10.1097/JU.0000000000000506.
    PubMed     Abstract available


  366. DAMBAL S, Howard LE, Allott EH, Aronson WJ, et al
    Serum Lipids Prior to Starting Androgen Deprivation Therapy and Risk of Castration-Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database.
    J Urol. 2019 Aug 20:101097JU0000000000000494. doi: 10.1097/JU.0000000000000494.
    PubMed     Abstract available


  367. ITO K, Yokomizo A, Tokunaga S, Arai G, et al
    Diagnostic Impacts of Clinical Laboratory-Based [-2] proPSA Indices on Any Grade, Gleason Grade Group >/=2 or >/=3 of Prostate Cancer in the PSA Below 10 ng/mL.
    J Urol. 2019 Aug 20:101097JU0000000000000495. doi: 10.1097/JU.0000000000000495.
    PubMed     Abstract available


  368. BAHLER CD, Green M, Hutchins GD, Cheng L, et al
    PSMA-Targeted Positron Emission Tomography (PET) in Evaluation of Patients with Primary Prostate Cancer: Comparison of Pre-operative [(68)Ga]Ga-PSMA-11 PET/CT, Immediate Post-operative Specimen [(68)Ga]Ga-PSMA-11 Imaging, and Whole Mount Pathology.
    J Urol. 2019 Aug 20:101097JU0000000000000501. doi: 10.1097/JU.0000000000000501.
    PubMed     Abstract available


  369. MAGANTY A, Sabik LM, Sun Z, Eom KY, et al
    Undertreatment of Prostate Cancer in Rural Residents.
    J Urol. 2019 Aug 20:101097JU0000000000000500. doi: 10.1097/JU.0000000000000500.
    PubMed     Abstract available


  370. TANEJA SS
    Re: Association of Treatment with 5alpha-Reductase Inhibitors with Time to Diagnosis and Mortality in Prostate Cancer.
    J Urol. 2019 Aug 12:10109701JU000058011614376.
    PubMed    


  371. KAPLAN SA
    Re: Association of Treatment with 5alpha-Reductase Inhibitors with Time to Diagnosis and Mortality in Prostate Cancer.
    J Urol. 2019 Aug 12:10109701JU00005798646485082.
    PubMed    


  372. TANEJA SS
    Re: Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer.
    J Urol. 2019 Aug 12:10109701JU000057984426332.
    PubMed    


  373. TANEJA SS
    Re: Recovery of Pad-Free Continence in Elderly Men Does Not Differ from Younger Men Undergoing Robot-Assisted Radical Prostatectomy for Aggressive Prostate Cancer.
    J Urol. 2019 Aug 12:101097JU0000000000000491. doi: 10.1097/JU.0000000000000491.
    PubMed    


  374. KAPLAN SA
    Re: Oxidative Damage in Patients with Benign Prostatic Hyperplasia and Prostate Cancer Co-Exposed to Phthalates and to Trace Elements.
    J Urol. 2019 Aug 12:10109701JU000057986087720.
    PubMed    


  375. RESNICK MJ
    Re: Association of Treatment with 5alpha-Reductase Inhibitors with Time to Diagnosis and Mortality in Prostate Cancer.
    J Urol. 2019 Aug 12:10109701JU00005798568009731.
    PubMed    


  376. XU L, Mao X, Grey A, Scandura G, et al
    Non-invasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells.
    J Urol. 2019 Aug 7:101097JU0000000000000475. doi: 10.1097/JU.0000000000000475.
    PubMed     Abstract available


  377. DAL MORO F, Pizzolito S
    Re: Transperineal Prostate Biopsies Using Local Anesthesia: Experience with 1,287 Patients. Prostate Cancer Detection Rate, Complications and Patient Tolerability.
    J Urol. 2019 Aug 7:101097JU0000000000000474. doi: 10.1097/JU.0000000000000474.
    PubMed    


  378. BUCKLEY RJ
    Re: Transperineal Prostate Biopsies Using Local Anesthesia: Experience with 1,287 Patients. Prostate Cancer Detection Rate, Complications and Patient Tolerability.
    J Urol. 2019 Aug 7:101097JU0000000000000473. doi: 10.1097/JU.0000000000000473.
    PubMed    


  379. SUNDI D, Nyame YA
    Editorial Comment.
    J Urol. 2019;202:254-255.
    PubMed    


  380. MOUL JW
    Editorial Comment.
    J Urol. 2019;202:254.
    PubMed    


  381. LUIS DE CASTRO ABREU A, Jadvar H
    Editorial Comment.
    J Urol. 2019;202:420-421.
    PubMed    


  382. STONE NN, Crawford ED, Skouteris VM, Arangua P, et al
    Reply by Authors.
    J Urol. 2019;202:271.
    PubMed    


  383. PORTER CR
    Editorial Comment.
    J Urol. 2019;202:270.
    PubMed    


  384. SANCHEZ-SALAS R, Stabile A
    Editorial Comment.
    J Urol. 2019;202:270-271.
    PubMed    


  385. EGGENER S
    Editorial Comment.
    J Urol. 2019;202:263.
    PubMed    


  386. SIEGEL C
    Re: Multiparametric MRI Features and Pathologic Outcome of Wedge-Shaped Lesions in the Peripheral Zone on T2-Weighted Images of the Prostate.
    J Urol. 2019;202:190.
    PubMed    


    July 2019
  387. ATALA A
    Re: ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.
    J Urol. 2019 Jul 31:10109701JU000057944436265.
    PubMed    


  388. JACOBS BL, Yabes JG, Lopa SH, Heron DE, et al
    The Influence of Stereotactic Body Radiation Therapy Adoption on Prostate Cancer Treatment Patterns.
    J Urol. 2019 Jul 30:101097JU0000000000000471. doi: 10.1097/JU.0000000000000471.
    PubMed     Abstract available


  389. OISHI M, Gill IS, Tafuri A, Shakir A, et al
    Hemi-Gland Cryoablation for Localized Low-, Intermediate- and High-Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 years.
    J Urol. 2019 Jul 26:101097JU0000000000000456. doi: 10.1097/JU.0000000000000456.
    PubMed     Abstract available


  390. TANEJA SS
    Re: Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
    J Urol. 2019 Jul 11:10109701JU0000577260122781.
    PubMed    


  391. TANEJA SS
    Re: Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
    J Urol. 2019 Jul 11:101097JU0000000000000443. doi: 10.1097/JU.0000000000000443.
    PubMed    


  392. ATALA A
    Re: The Proteogenomic Landscape of Curable Prostate Cancer.
    J Urol. 2019 Jul 9:10109701JU000057698013730.
    PubMed    


  393. SIEGEL C
    Re: PTEN Expression in Prostate Cancer: Relationship with Clinicopathologic Features and Multiparametric MRI Findings.
    J Urol. 2019 Jul 8:101097JU0000000000000428. doi: 10.1097/JU.0000000000000428.
    PubMed    


  394. WALTON-DIAZ A, Madariaga-Venegas M
    Editorial Comment.
    J Urol. 2019;202:106-107.
    PubMed    


  395. FRASER M
    Editorial Comment.
    J Urol. 2019;202:95.
    PubMed    


  396. KLEIN EA
    Editorial Comment.
    J Urol. 2019;202:101.
    PubMed    


  397. BRAVI CA, Tin A, Vertosick E, Mazzone E, et al
    The Impact of Experience on the Risk of Surgical Margins and Biochemical Recurrence after Robot-Assisted Radical Prostatectomy: A Learning Curve Study.
    J Urol. 2019;202:108-113.
    PubMed     Abstract available


    June 2019
  398. HANSON HA, Martin C, O'Neil B, Leiser CL, et al
    The Relative Importance of Race Compared to Healthcare and Social Factors in Predicting Prostate Cancer Mortality: A Random Forest Approach.
    J Urol. 2019 Jun 27:101097JU0000000000000416. doi: 10.1097/JU.0000000000000416.
    PubMed     Abstract available


  399. MANNAERTS CK, Wildeboer RR, Remmers S, van Kollenburg RAA, et al
    Multiparametric ultrasound for prostate cancer detection and localization: Correlation of B-mode, shearwave elastography and contrast-enhanced ultrasound with radical prostatectomy specimens.
    J Urol. 2019 Jun 27:101097JU0000000000000415. doi: 10.1097/JU.0000000000000415.
    PubMed     Abstract available


  400. FAROLFI A, Gafita A, Calais J, Eiber M, et al
    (68)Ga-PSMA-11 PET Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study.
    J Urol. 2019 Jun 24:101097JU0000000000000417. doi: 10.1097/JU.0000000000000417.
    PubMed     Abstract available


  401. TANEJA SS
    Re: Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsies.
    J Urol. 2019 Jun 24:10109701JU000056971634429.
    PubMed    


  402. RESNICK MJ
    Re: Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends across Risk Groups in the United States, 2010-2015.
    J Urol. 2019 Jun 24:10109701JU000057441601701.
    PubMed    


  403. TANEJA SS
    Re: Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends across Risk Groups in the United States, 2010-2015.
    J Urol. 2019 Jun 24:10109701JU00005749769074752.
    PubMed    


  404. FRIEDLANDER TW, Welty C, Anantharaman A, Schonhoft JD, et al
    Identification and Characterization of Circulating Tumor Cells in Men Who Have Undergone Prostatectomy for Clinically Localized, High - Risk Prostate Cancer.
    J Urol. 2019 Jun 19:101097JU0000000000000393. doi: 10.1097/JU.0000000000000393.
    PubMed     Abstract available


  405. LAVIANA AA, Hernandez A, Huang LC, Zhao Z, et al
    Interpretation of domain scores on the expanded prostate cancer index composite: How does the domain score translate into functional outcomes?
    J Urol. 2019 Jun 19:101097JU0000000000000392. doi: 10.1097/JU.0000000000000392.
    PubMed     Abstract available


  406. MARGEL D, Peer A, Ber Y, Shavit-Grievink L, et al
    Cardiovascular morbidity in a randomized trial comparing GnRH-agonist and GnRH-antagonist among patients with advanced prostate-cancer and pre-existing cardiovascular disease.
    J Urol. 2019 Jun 12:101097JU0000000000000384. doi: 10.1097/JU.0000000000000384.
    PubMed     Abstract available


  407. ATALA A
    Re: Inhibition of De Novo Lipogenesis Targets Androgen Receptor Signaling in Castration-Resistant Prostate Cancer.
    J Urol. 2019 Jun 10:101097JU0000000000000379. doi: 10.1097/JU.0000000000000379.
    PubMed    


  408. SIEGEL C
    Re: A Grading System for the Assessment of Risk of Extraprostatic Extension of Prostate Cancer at Multiparametric MRI.
    J Urol. 2019 Jun 5:101097JU0000000000000371. doi: 10.1097/JU.0000000000000371.
    PubMed    


  409. SHAH N, Ioffe V
    Re: Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years. Keyan Salari et al. JOU. Vol 201, 721-727, April 2019.
    J Urol. 2019 Jun 4:101097JU0000000000000362. doi: 10.1097/JU.0000000000000362.
    PubMed    


  410. SALARI K, Feldman AS
    Re: Salari et al. Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years. JUrol. Vol 201, 721-727, April 2019.
    J Urol. 2019 Jun 4:101097JU0000000000000363. doi: 10.1097/JU.0000000000000363.
    PubMed    


  411. FERNANDO H, Garcia C, Hossack T, Ahmadi N, et al
    Incidence, Predictive Factors and Preventive Measures for Inguinal Hernia following Robotic and Laparoscopic Radical Prostatectomy: A Systematic Review.
    J Urol. 2019;201:1072-1079.
    PubMed     Abstract available


  412. GRUMMET J
    Editorial Comment.
    J Urol. 2019;201:1126.
    PubMed    


  413. AYDIN AM, Pow-Sang JM
    Editorial Comment.
    J Urol. 2019;201:1125-1126.
    PubMed    


  414. CROOK J
    Editorial Comment.
    J Urol. 2019;201:1133.
    PubMed    


  415. THOMPSON JE, Sridhar AN, Tan WS, Freeman A, et al
    Pathological Findings and Magnetic Resonance Imaging Concordance at Salvage Radical Prostatectomy for Local Recurrence following Partial Ablation Using High Intensity Focused Ultrasound.
    J Urol. 2019;201:1134-1143.
    PubMed     Abstract available


    May 2019
  416. HANNA N, Wszolek MF, Mojtahed A, Nicaise E, et al
    MULTIPARAMETRIC MRI/ULTRASOUND FUSION BIOPSY IMPROVES BUT DOES NOT REPLACE STANDARD TEMPLATE BIOPSY FOR THE DETECTION OF PROSTATE CANCER.
    J Urol. 2019 May 30:101097JU0000000000000359. doi: 10.1097/JU.0000000000000359.
    PubMed     Abstract available


  417. GROSS MD, Sedrakyan A, Bianco FJ, Carroll PR, et al
    Study of Prostate Ablation Related Energy Devices (SPARED) Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer.
    J Urol. 2019 May 30:101097JU0000000000000357. doi: 10.1097/JU.0000000000000357.
    PubMed     Abstract available


  418. MURALIDHAR V, Mahal BA, Butler S, Lamba N, et al
    Combined external beam radiation therapy and brachytherapy versus radical prostatectomy with adjuvant radiation therapy for Gleason 9-10 prostate cancer.
    J Urol. 2019 May 30:101097JU0000000000000352. doi: 10.1097/JU.0000000000000352.
    PubMed     Abstract available


  419. GULATI R, Psutka SP, Etzioni R
    Personalized risks of overdiagnosis for screen-detected prostate cancer incorporating patient comorbidities: Estimation and communication.
    J Urol. 2019 May 21:101097JU0000000000000346. doi: 10.1097/JU.0000000000000346.
    PubMed     Abstract available


  420. SHARMA V, Wymer KM, Borah BJ, Barocas DA, et al
    Cost-Effectiveness of Active Surveillance, Radical Prostatectomy, and External Beam Radiotherapy for Localized Prostate Cancer: An Analysis of the ProtecT Trial.
    J Urol. 2019 May 21:101097JU0000000000000345. doi: 10.1097/JU.0000000000000345.
    PubMed     Abstract available


  421. ZUNIGA KB, Zhao S, Kenfield SA, Cedars B, et al
    Trends in complementary and alternative medicine use among patients with prostate cancer.
    J Urol. 2019 May 15:101097JU0000000000000336. doi: 10.1097/JU.0000000000000336.
    PubMed     Abstract available


  422. GRIEBLING TL
    Re: Systematic Review and Network Meta-Analysis on the Relative Efficacy of Osteoporotic Medications: Men with Prostate Cancer on Continuous Androgen-Deprivation Therapy to Reduce Risk of Fragility Fractures.
    J Urol. 2019 May 10:10109701JU000055973645783.
    PubMed    


  423. GONTERO P, Marra G, Alessio P, Filippini C, et al
    Salvage radical prostatectomy for recurrent prostate cancer: morbidity and functional outcomes from a large multicenter series of open versus robotic approaches.
    J Urol. 2019 May 10:101097JU0000000000000327. doi: 10.1097/JU.0000000000000327.
    PubMed     Abstract available


  424. TANEJA SS
    Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up.
    J Urol. 2019 May 7:101097JU0000000000000323. doi: 10.1097/JU.0000000000000323.
    PubMed    


  425. TANEJA SS
    Re: A 17-Gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility.
    J Urol. 2019 May 7:10109701JU0000559603179075.
    PubMed    


  426. ATALA A
    Re: Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.
    J Urol. 2019 May 7:101097JU0000000000000330. doi: 10.1097/JU.0000000000000330.
    PubMed    


  427. ATALA A
    Re: Inhibition of De Novo Lipogenesis Targets Androgen Receptor Signaling in Castration-Resistant Prostate Cancer.
    J Urol. 2019 May 7:10109701JU0000559616036260.
    PubMed    


  428. TOM MC, Nguyen JK, Luciano R, Mian OY, et al
    Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy.
    J Urol. 2019 May 6:101097JU0000000000000316. doi: 10.1097/JU.0000000000000316.
    PubMed     Abstract available


  429. MORTEZAVI A, Krauter J, Gu DA, Sonderer J, et al
    Extensive histological sampling following focal therapy of clinically significant prostate cancer with high-intensity focused ultrasound.
    J Urol. 2019 May 1:101097JU0000000000000298. doi: 10.1097/JU.0000000000000298.
    PubMed     Abstract available


  430. CARTER HB
    Editorial Comment.
    J Urol. 2019;201:922.
    PubMed    


  431. DALL'ERA M
    Editorial Comment.
    J Urol. 2019;201:935-936.
    PubMed    


  432. MOORE C
    Editorial Comment.
    J Urol. 2019;201:928.
    PubMed    


  433. SRIVASTAVA A, Joshi SS
    Editorial Comment.
    J Urol. 2019;201:949.
    PubMed    


  434. FAISAL FA, Tosoian JJ, Han M, Macura KJ, et al
    Clinical, Pathological and Oncologic Findings of Radical Prostatectomy with Extraprostatic Extension Diagnosed on Preoperative Prostate Biopsy.
    J Urol. 2019;201:937-942.
    PubMed     Abstract available


    April 2019
  435. HAESE A, Trooskens G, Steyaert S, Hessels D, et al
    Multicenter optimization and validation of a 2-gene mRNA urine test for detection of clinically significant prostate cancer prior to initial prostate biopsy.
    J Urol. 2019 Apr 26:101097JU0000000000000293. doi: 10.1097/JU.0000000000000293.
    PubMed     Abstract available


  436. JOHNSON DC, Kwok E, Ahn C, Pashchinskiy A, et al
    Financial Margins for Prostate Cancer Surgery: Quantifying the Impact of Modifiable Cost Inputs in an Episode-based Reimbursement Model.
    J Urol. 2019 Apr 22:101097JU0000000000000283. doi: 10.1097/JU.0000000000000283.
    PubMed     Abstract available


  437. DASKIVICH TJ, Thomas IC, Luu M, Shelton JB, et al
    External Validation of the Prostate Cancer-Specific Comorbidity Index (PCCI), a Claims-Based Tool for Prediction of Life Expectancy in Men with Prostate Cancer.
    J Urol. 2019 Apr 22:101097JU0000000000000287. doi: 10.1097/JU.0000000000000287.
    PubMed     Abstract available


  438. TANEJA SS
    Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): a Randomised Controlled Phase 3 Trial.
    J Urol. 2019 Apr 8:10109701JU00005577560832916.
    PubMed    


  439. TANEJA SS
    Re: Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.
    J Urol. 2019 Apr 8:101097JU0000000000000276. doi: 10.1097/JU.0000000000000276.
    PubMed    


  440. TEWARI AK, Taouli B
    Radiomics features measured with multiparametric MRI predict prostate cancer aggressiveness.
    J Urol. 2019 Apr 8:101097JU0000000000000272. doi: 10.1097/JU.0000000000000272.
    PubMed     Abstract available


  441. CEDARS BE, Washington SL 3rd, Cowan JE, Leapman M, et al
    STABILITY OF A 17-GENE GENOMIC PROSTATE SCORE IN SERIAL TESTING OF MEN ON ACTIVE SURVEILLANCE FOR EARLY STAGE PROSTATE CANCER.
    J Urol. 2019 Apr 8:101097JU0000000000000271. doi: 10.1097/JU.0000000000000271.
    PubMed     Abstract available


  442. SHOAG J, Liu D, Ma X, Oromendia C, et al
    MP68-12 IMPACT OF SPOP MUTATION ON PROSTATE CANCER PROGNOSIS.
    J Urol. 2019;201.
    PubMed     Abstract available


  443. SANDHU HS, Mulholland DJ
    MP68-11 IDENTIFICATION OF INTERMEDIATE CELL POPULATIONS DURING TREATMENT INDUCED LINEAGE CONVERSION TO NEUROENDOCRINE PROSTATE CANCER.
    J Urol. 2019;201.
    PubMed     Abstract available


  444. VELLKY J, Ricke W
    MP68-13 DDX3-MEDIATED TRANSLATIONAL REGULATION OF ANDROGEN RECEPTOR IN PROSTATE CANCER PROGRESSION.
    J Urol. 2019;201.
    PubMed     Abstract available


  445. FAISAL F, Alshalalfa M, Davicioni E, Karnes RJ, et al
    MP68-10 HOXB13 EXPRESSION AND ITS ROLE IN PROSTATE CANCER PROGRESSION AND NEUROENDOCRINE DIFFERENTIATION.
    J Urol. 2019;201.
    PubMed     Abstract available


  446. JAMASPISHVILI T, Patel P, Niu Y, Vidotto T, et al
    MP28-02 QUANTITATIVE MEASUREMENT OF PTEN LOSS IMPROVES RISK ASSESSMENT IN PROSTATE CANCER.
    J Urol. 2019;201.
    PubMed     Abstract available


  447. ADSHEAD J, Oldfield F, Hadaschik B, Wouter Everaerts JA, et al
    MP20-04 USABILITY AND TECHNICAL FEASIBILITY EVALUATION OF A TETHERED LAPAROSCOPIC GAMMA PROBE FOR RADIOGUIDED SURGERY IN PROSTATE CANCER: A PELVIC PHANTOM AND PORCINE MODEL STUDY.
    J Urol. 2019;201.
    PubMed     Abstract available


  448. RICHIE JP
    Re: Association between Vasectomy and Risk of Testicular Cancer: A Systematic Review and Meta-Analysis.
    J Urol. 2019;201:667-668.
    PubMed    


  449. TOSOIAN JJ, George AK
    Editorial Comment.
    J Urol. 2019;201:727.
    PubMed    


  450. HARPER BT, Dykes TE, Terris MK
    Editorial Comment.
    J Urol. 2019;201:749.
    PubMed    


  451. SAMMON J
    Editorial Comment.
    J Urol. 2019;201:733-734.
    PubMed    


  452. GRUBB R
    Editorial Comment.
    J Urol. 2019;201:740-741.
    PubMed    


  453. KEEGAN KA
    Editorial Comment.
    J Urol. 2019;201:749.
    PubMed    


  454. DASKIVICH TJ
    Editorial Comment.
    J Urol. 2019;201:733.
    PubMed    


  455. CARROLL P, Schmidt B
    Editorial Comment.
    J Urol. 2019;201:820.
    PubMed    


  456. MARTIN C, Haaland B, Tward AE, Dechet C, et al
    Describing the Spectrum of Patient Reported Outcomes after Radical Prostatectomy: Providing Information to Improve Patient Counseling and Shared Decision Making.
    J Urol. 2019;201:751-758.
    PubMed     Abstract available


    March 2019
  457. ATALA A
    Re: Alterations of Tumor Microenvironment by Nitric Oxide Impedes Castration-Resistant Prostate Cancer Growth.
    J Urol. 2019 Mar 29:101097JU0000000000000251. doi: 10.1097/JU.0000000000000251.
    PubMed    


  458. RESNICK MJ
    Re: Risk of Prostate Cancer in Men Treated with 5alpha-Reductase Inhibitors-A Large Population-Based Prospective Study.
    J Urol. 2019 Mar 29:10109701JU00005577312536940.
    PubMed    


  459. ATALA A
    Re: Targeting FOXA1-Mediated Repression of TGF-beta Signaling Suppresses Castration-Resistant Prostate Cancer Progression.
    J Urol. 2019 Mar 29:10109701JU000055773048240.
    PubMed    


  460. PAK S, Park SY, Shin TJ, You D, et al
    Association of muscle mass with survival after radical prostatectomy in patients with prostate cancer.
    J Urol. 2019 Mar 27:101097JU0000000000000249. doi: 10.1097/JU.0000000000000249.
    PubMed     Abstract available


  461. TANEJA SS
    Re: Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging.
    J Urol. 2019 Mar 13:101097JU0000000000000231. doi: 10.1097/JU.0000000000000231.
    PubMed    


  462. AMINSHARIFI A, Simon R, Polascik TJ, Robertson CN, et al
    Evaluation and active treatment versus active surveillance of localized prostate cancer in renal transplant patients in the era of low and very low risk prostate cancer.
    J Urol. 2019 Mar 5:101097JU0000000000000207. doi: 10.1097/JU.0000000000000207.
    PubMed     Abstract available


  463. STONE NN, Crawford ED, Skouteris VM, Arangua P, et al
    The ratio of the number of biopsy specimens to prostate volume (biopsy density) > 1.5 improves the prostate cancer detection rate in men undergoing transperineal biopsy of the prostate.
    J Urol. 2019 Mar 5:101097JU0000000000000204. doi: 10.1097/JU.0000000000000204.
    PubMed     Abstract available


  464. WANG CS, Jhan JH, Li CC
    Re: Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer when the Prostate Specific Antigen is in the Diagnostic Gray Zone: .: A. Aminsharifi, L. Howard, Y. Wu, A. De Hoedt, C. Bailey, S. J. Freedland and T. J. Po
    J Urol. 2019;201:627-628.
    PubMed    


  465. MORGAN SC, Hoffman K, Loblaw DA, Buyyounouski MK, et al
    Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline.
    J Urol. 2019;201:528-534.
    PubMed     Abstract available


  466. BRYANT RJ, Hobbs CP, Eyre KS, Davies LC, et al
    Comparison of Prostate Biopsy with or without Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: An Observational Cohort Study.
    J Urol. 2019;201:510-519.
    PubMed     Abstract available


  467. MIRAK SA, Shakeri S, Bajgiran AM, Felker ER, et al
    Three Tesla Multiparametric Magnetic Resonance Imaging: Comparison of Performance with and without Endorectal Coil for Prostate Cancer Detection, PI-RADS version 2 Category and Staging with Whole Mount Histopathology Correlation.
    J Urol. 2019;201:496-502.
    PubMed     Abstract available


  468. LI-SHENG CHEN S, Ching-Yuan Fann J, Sipeky C, Yang TK, et al
    Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen.
    J Urol. 2019;201:486-495.
    PubMed     Abstract available


  469. ATALA A
    Re: Large-Scale Transcriptome-Wide Association Study Identifies New Prostate Cancer Risk Regions.
    J Urol. 2019;201:447.
    PubMed    


  470. ATALA A
    Re: Diverse AR-V7 Cistromes in Castration-Resistant Prostate Cancer are Governed by HoxB13.
    J Urol. 2019;201:446-447.
    PubMed    


  471. TANEJA SS
    Re: A Multicentre Study of 5-Year Outcomes following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer.
    J Urol. 2019;201:443-444.
    PubMed    


  472. TANEJA SS
    Re: Association between Prostate Magnetic Resonance Imaging and Observation for Low-Risk Prostate Cancer.
    J Urol. 2019;201:443.
    PubMed    


  473. HELFAND BT
    Editorial Comment.
    J Urol. 2019;201:494.
    PubMed    


  474. EPSTEIN J
    Editorial Comment.
    J Urol. 2019;201:540.
    PubMed    


  475. MORASH C
    Editorial Comment.
    J Urol. 2019;201:527.
    PubMed    


  476. ABDI H, Breau RH
    Editorial Comment.
    J Urol. 2019;201:518.
    PubMed    


  477. WANG S, Siddiqui MM
    Editorial Comment.
    J Urol. 2019;201:509.
    PubMed    


    February 2019
  478. FEI B, Abiodun-Ojo OA, Akintayo AA, Akin-Akintayo O, et al
    Feasibility and Initial Results: Fluciclovine PET/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer.
    J Urol. 2019 Feb 28:101097JU0000000000000200. doi: 10.1097/JU.0000000000000200.
    PubMed     Abstract available


  479. TAN N, Bavadian N, Calais J, Oyoyo U, et al
    Imaging of PSMA-targeted Radiotracers for the Detection of Prostate Cancer Biochemical Recurrence After Definitive Therapy: A Systematic Review and Meta-analysis.
    J Urol. 2019 Feb 25:101097JU0000000000000198. doi: 10.1097/JU.0000000000000198.
    PubMed     Abstract available


  480. GREENLAND NY, Zhang L, Cowan JE, Carroll PR, et al
    Correlation of a Commercial Genomic Risk Classifier with Histologic Patterns in Prostate Cancer.
    J Urol. 2019 Feb 15:101097JU0000000000000175. doi: 10.1097/JU.0000000000000175.
    PubMed     Abstract available


  481. STOVSKY M, Klein EA, Chait A, Manickam K, et al
    Clinical Validation of IsoPSA, a Single Parameter, Structure-Based Assay for Improved Detection of High-Grade Prostate Cancer.
    J Urol. 2019 Feb 15:101097JU0000000000000185. doi: 10.1097/JU.0000000000000185.
    PubMed     Abstract available


  482. ECHEVARRIA MI, Awasthi S, Cheng CH, Berglund AE, et al
    African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome.
    J Urol. 2019 Feb 15:101097JU0000000000000193. doi: 10.1097/JU.0000000000000193.
    PubMed     Abstract available


  483. GAFFNEY C, Golan R, Cantu MD, Scognamiglio T, et al
    The Clinical Utility of the Genomic Prostate Score in Men with Very Low to Intermediate Risk Prostate Cancer.
    J Urol. 2019 Feb 12:101097JU0000000000000170. doi: 10.1097/JU.0000000000000170.
    PubMed     Abstract available


  484. TANEJA SS
    Re: Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) versus Conventionally Fractionated IMRT for Localized Prostate Cancer.
    J Urol. 2019 Feb 8. doi: 10.1097/JU.0000000000000169.
    PubMed    


  485. TANEJA SS
    Re: Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
    J Urol. 2019 Feb 8. doi: 10.1097/01.JU.0000554059.66296.
    PubMed    


  486. STEFANOVA V, Buckley R, Flax S, Spevack L, et al
    Transperineal prostate biopsies under local anesthetic: Experience with 1287 patients Prostate cancer detection rate, complications and patient tolerability.
    J Urol. 2019 Feb 8:101097JU0000000000000156. doi: 10.1097/JU.0000000000000156.
    PubMed     Abstract available


  487. DAMODARAN S, Lang JM, Jarrard DF
    Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    J Urol. 2019 Feb 7. doi: 10.1097/JU.0000000000000117.
    PubMed     Abstract available


  488. ATALA A
    Re: Classification of Prostate Cancer Using a Protease Activity Nanosensor Library.
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000554005.76376.
    PubMed    


  489. ATALA A
    Re: Immunogenomic Analyses Associate Immunological Alterations with Mismatch Repair Defects in Prostate Cancer.
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000554004.38258.
    PubMed    


  490. GRIEBLING TL
    Re: Localised Prostate Cancer in Elderly Men Aged 80-89 Years, Findings from a Population-Based Registry.
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000553998.44096.
    PubMed    


  491. GRIEBLING TL
    Re: Alzheimer's Disease is Associated with Prostate Cancer: .
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000553997.66966.
    PubMed    


  492. DAS S, Salami SS, Spratt DE, Kaffenberger SD, et al
    Bringing prostate cancer germline genetics into clinical practice.
    J Urol. 2019 Feb 5. doi: 10.1097/JU.0000000000000137.
    PubMed     Abstract available


  493. ZELEFSKY MJ, Goldman DA, Reuter V, Kollmeier M, et al
    Long-Term Implications of a Positive Post Treatment Biopsy Among Patients Treated with External Beam Radiotherapy for Clinically Localized Prostate Cancer.
    J Urol. 2019 Feb 5. doi: 10.1097/JU.0000000000000110.
    PubMed     Abstract available


  494. FALAGARIO UG, Beksac AT, Martini A, Cumarasamy S, et al
    Defining Prostate Cancer at Favorable Intermediate Risk: the Potential Utility Of Magnetic Resonance Imaging And Genomic Tests.
    J Urol. 2019 Feb 4. doi: 10.1097/JU.0000000000000134.
    PubMed     Abstract available


  495. ATALA A
    Re: TRAF4-Mediated Ubiquitination of NGF Receptor TrkA Regulates Prostate Cancer Metastasis.
    J Urol. 2019;201:230.
    PubMed    


  496. ATALA A
    Re: A Somatically Acquired Enhancer of the Androgen Receptor is a Noncoding Driver in Advanced Prostate Cancer.
    J Urol. 2019;201:230.
    PubMed    


  497. TANEJA SS
    Re: Role of the 4Kscore Test as a Predictor of Reclassification in Prostate Cancer Active Surveillance.
    J Urol. 2019;201:228.
    PubMed    


  498. TANEJA SS
    Re: Histologic Findings Associated with False Positive Multiparametric Magnetic Resonance Imaging Performed for Prostate Cancer Detection.
    J Urol. 2019;201:227-228.
    PubMed    


  499. SIEGEL C
    Re: Validation of PI-RADS Version 2 in Transition Zone Lesions for the Detection of Prostate Cancer.
    J Urol. 2019;201:208.
    PubMed    


  500. TILKI D
    Editorial Comment.
    J Urol. 2019;201:340.
    PubMed    


  501. SCARSBROOK A
    Editorial Comment.
    J Urol. 2019;201:331.
    PubMed    


  502. BREAU RH, Kumar R
    Editorial Comment.
    J Urol. 2019;201:331.
    PubMed    


  503. THOMPSON JE, Stricker PD
    Editorial Comment.
    J Urol. 2019;201:306-307.
    PubMed    


  504. CARROLL P
    Editorial Comment.
    J Urol. 2019;201:298-299.
    PubMed    


  505. CHUA MLK
    Editorial Comment.
    J Urol. 2019;201:291.
    PubMed    


  506. BREAU RH, Kumar R
    Editorial Comment.
    J Urol. 2019;201:290-291.
    PubMed    


  507. WANG S, Siddiqui MM
    Editorial Comment.
    J Urol. 2019;201:277.
    PubMed    


  508. GRUMMET J
    Editorial Comment.
    J Urol. 2019;201:276.
    PubMed    


  509. MOSES KA
    Editorial Comment.
    J Urol. 2019;201:267.
    PubMed    


  510. EGGENER S
    Editorial Comment.
    J Urol. 2019;201:266-267.
    PubMed    


  511. PIERRARD V, Lebdai S, Kleinclauss F, Azzouzi AR, et al
    Radical Prostatectomy after Vascular Targeted Photodynamic Therapy with Padeliporfin: Feasibility, and Early and Intermediate Results.
    J Urol. 2019;201:315-321.
    PubMed     Abstract available


  512. KIRMIZ S, Qi J, Babitz SK, Linsell S, et al
    Grade Groups Provide Improved Predictions of Pathological and Early Oncologic Outcomes Compared with Gleason Score Risk Groups.
    J Urol. 2019;201:278-283.
    PubMed     Abstract available


    January 2019
  513. BOTEJUE M, Abbott D, Danella J, Fonshell C, et al
    Utilization of Active Surveillance as Initial Management of Newly Diagnosed Prostate Cancer: Data from the PURC.
    J Urol. 2019 Jan 31. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  514. BURNS JF, Hurwitz LM, Levie KE, Caumont F, et al
    Impact of Subsequent Biopsies on Comprehensive Health Related Quality of Life in Patients With and Without Prostate Cancer.
    J Urol. 2019 Jan 25. doi: 10.1097/JU.0000000000000024.
    PubMed     Abstract available


  515. GINSBURG KB, Arcot R, Qi J, Linsell SM, et al
    Confirmatory MRI With or Without Biopsy Impacts Decision-Making in Newly Diagnosed Favorable Risk Prostate Cancer.
    J Urol. 2019 Jan 25. doi: 10.1097/JU.0000000000000059.
    PubMed     Abstract available


  516. GOLD SA, Shih JH, Rais-Bahrami S, Bloom JB, et al
    When to Biopsy the Seminal Vesicles: A Validated Multiparametric Magnetic Resonance Imaging and Target Driven Model to Detect Seminal Vesicle Invasion in Prostate Cancer.
    J Urol. 2019 Jan 23. doi: 10.1097/JU.0000000000000112.
    PubMed     Abstract available


  517. YAXLEY JW, Raveenthiran S, Nouhaud FX, Samartunga H, et al
    Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with 68Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology: Can Preoperative 68Ga-PSMA Po
    J Urol. 2019 Jan 21. doi: 10.1097/JU.0000000000000053.
    PubMed     Abstract available


  518. SALARI K, Kuppermann D, Preston MA, Dahl DM, et al
    Active Surveillance of Prostate Cancer is a Viable Option in Men Younger Than 60 Years.
    J Urol. 2019 Jan 16. doi: 10.1097/JU.0000000000000031.
    PubMed     Abstract available


  519. TANEJA SS
    Re: Transcriptomic Heterogeneity in Multifocal Prostate Cancer.
    J Urol. 2019 Jan 15. doi: 10.1097/JU.0000000000000101.
    PubMed    


  520. TANEJA SS
    Re: Olaparib Combined with Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer: .
    J Urol. 2019 Jan 15. doi: 10.1097/01.JU.0000553310.60445.
    PubMed    


  521. ATALA A
    Re: Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import.
    J Urol. 2019 Jan 15. doi: 10.1097/JU.0000000000000096.
    PubMed    


  522. ZHAO J, Liu J, Sun G, Zhang M, et al
    The Prognostic Value of the Proportion and Architectural Patterns of Intraductal Carcinoma of the Prostate in Patients with de Novo Metastatic Prostate Cancer.
    J Urol. 2019 Jan 15. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  523. HUANG H, Muscatelli S, Naslund M, Badiyan SN, et al
    Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger Than 60 Years.
    J Urol. 2019;201:120-128.
    PubMed     Abstract available


  524. BASS R, Fleshner N, Finelli A, Barkin J, et al
    Oncologic and Functional Outcomes of Partial Gland Ablation with High Intensity Focused Ultrasound for Localized Prostate Cancer.
    J Urol. 2019;201:113-119.
    PubMed     Abstract available


  525. FAIENA I, Salmasi A, Mendhiratta N, Markovic D, et al
    PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    J Urol. 2019;201:91-97.
    PubMed     Abstract available


  526. BLOOM JB, Hale GR, Gold SA, Rayn KN, et al
    Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: Role of a Negative Confirmatory Magnetic Resonance Imaging-Ultrasound Fusion Biopsy.
    J Urol. 2019;201:84-90.
    PubMed     Abstract available


  527. ATALA A
    Re: Diverse AR-V7 Cistromes in Castration-Resistant Prostate Cancer are Governed by HoxB13.
    J Urol. 2019;201:33-34.
    PubMed    


  528. ATALA A
    Re: Acquisition of Tumorigenic Potential and Therapeutic Resistance in CD133+ Subpopulation of Prostate Cancer Cells Exhibiting Stem-Cell Like Characteristics.
    J Urol. 2019;201:33.
    PubMed    


  529. TANEJA SS
    Re: Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
    J Urol. 2019;201:31.
    PubMed    


  530. CATHELINEAU X, Sanchez-Salas R
    Editorial Comment.
    J Urol. 2019;201:119.
    PubMed    


  531. STERNBERG IA
    Editorial Comment.
    J Urol. 2019;201:104.
    PubMed    


  532. DASKIVICH TJ
    Editorial Comment.
    J Urol. 2019;201:104.
    PubMed    


  533. GLASER ZA, Rais-Bahrami S
    Editorial Comment.
    J Urol. 2019;201:90.
    PubMed    


  534. PUNNEN S
    Editorial Comment.
    J Urol. 2019;201:83.
    PubMed    


  535. PERLIS N
    Editorial Comment.
    J Urol. 2019;201:82.
    PubMed    


  536. SIVARAMAN A, Kim EH, Andriole GL
    Editorial Comment.
    J Urol. 2019;201:112.
    PubMed    


    December 2018
  537. FRIEDLANDER DF, von Landenberg N, Loppenberg B, Noldus J, et al
    Facility-Level Variation In Rates Of Definitive Therapy For Low-Risk Prostate Cancer Among Men With Limited Life Expectancy: An Opportunity For Value-Based Care Redesign.
    J Urol. 2018 Dec 24. doi: 10.1097/JU.0000000000000006.
    PubMed     Abstract available


  538. BEKSAC AT, Cumarasamy S, Falagario U, Xu P, et al
    Multiparametric Magnetic Resonance Imaging Features Identify Aggressive Prostate Cancer at the Phenotypic and Transcriptomic Level.
    J Urol. 2018;200:1241-1249.
    PubMed     Abstract available


    November 2018
  539. KRIMPHOVE MJ, Fletcher SA, Cole AP, Berg S, et al
    Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals.
    J Urol. 2018 Nov 8. pii: S0022-5347(18)44053-0. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  540. TANEJA SS
    Re: Effects of Pathological Upstaging or Upgrading on Metastasis and Cancer-Specific Mortality in Men with Clinical Low-Risk Prostate Cancer.
    J Urol. 2018;200:945-946.
    PubMed    


  541. TANEJA SS
    Re: Germline DNA-Repair Gene Mutations and Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Receiving First-Line Abiraterone and Enzalutamide.
    J Urol. 2018;200:945.
    PubMed    


  542. TANEJA SS
    Re: Circulating microRNAs and Treatment Response in the Phase II SWOG S0925 Study for Patients with New Metastatic Hormone-Sensitive Prostate Cancer.
    J Urol. 2018;200:944-946.
    PubMed    


  543. RESNICK MJ
    Re: Quality of Life during Treatment with Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.
    J Urol. 2018;200:936.
    PubMed    


    October 2018
  544. CHEN SL, Fann JC, Sipeky C, Yang TK, et al
    Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms (SNPs) and Prostate-Specific Antigen (PSA).
    J Urol. 2018 Oct 23. pii: S0022-5347(18)44024-4. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  545. ETHERIDGE T, Liou JI, Downs TM, Abel EJ, et al
    The Impact of Agent Orange Exposure on Prostate Cancer Outcomes.
    J Urol. 2018 Oct 12. pii: S0022-5347(18)43983-3. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  546. WALTON E, Yaguchi G, Keeley J, Deebajah M, et al
    Effect of Lesion Location on Prostate Cancer Detection Rate with Magnetic Resonance Imaging Targeted Biopsy in African Americans.
    J Urol. 2018 Oct 11. pii: S0022-5347(18)43980-8. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  547. MORGAN SC, Hoffman K, Loblaw DA, Buyyounouski MK, et al
    Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline.
    J Urol. 2018 Oct 9. pii: S0022-5347(18)43963-8. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  548. ITO Y, Udo K, Vertosick EA, Sjoberg DD, et al
    Clinical Utility of Prostate and Tumor Volume-Related Parameters Following Radical Prostatectomy for Localized Prostate Cancer.
    J Urol. 2018 Oct 6. pii: S0022-5347(18)43967-5. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  549. ATALA A
    Re: Compartmentalized Activities of the Pyruvate Dehydrogenase Complex Sustain Lipogenesis in Prostate Cancer.
    J Urol. 2018;200:701-702.
    PubMed    


  550. TANEJA SS
    Re: Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.
    J Urol. 2018;200:699.
    PubMed    


  551. TANEJA SS
    Re: Short-Term Effects of Transdermal Estradiol in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer: A Randomized Placebo-Controlled Trial.
    J Urol. 2018;200:698-699.
    PubMed    


  552. TANEJA SS
    Re: MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.
    J Urol. 2018;200:697-699.
    PubMed    


  553. RESNICK MJ
    Re: Using Medicare Claims to Examine Long-Term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial.
    J Urol. 2018;200:689.
    PubMed    


    September 2018
  554. AFSHARI MIRAK S, Shakeri S, Mohammadian Bajgiran A, Felker ER, et al
    3T Multiparametric MRI: Comparison of Performance With and Without Endorectal Coil for Prostate Cancer Detection, PI-RADSv2 Category and Staging with Whole Mount Histopathology Correlation in 429 Patients.
    J Urol. 2018 Sep 28. pii: S0022-5347(18)43960-2. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  555. BRYANT RJ, Hobbs CP, Eyre KS, Davies LC, et al
    Comparison of prostate biopsy with or without pre-biopsy multi-parametric MRI in prostate cancer detection: an observational cohort study.
    J Urol. 2018 Sep 25. pii: S0022-5347(18)43943-2. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  556. THOMSEN FB, Jakobsen H, Langkilde NC, Borre M, et al
    Active surveillance for localized prostate cancer. Nationwide, observational study.
    J Urol. 2018 Sep 18. pii: S0022-5347(18)43911-0. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  557. LOEB S, Folkvaljon Y, Bratt O, Robinson D, et al
    Defining Intermediate-Risk Prostate Cancer Suitable for Active Surveillance.
    J Urol. 2018 Sep 18. pii: S0022-5347(18)43908-0. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  558. BALAKRISHNAN AS, Palmer NR, Fergus KB, Gaither TW, et al
    Minority recruitment trends in phase III prostate cancer clinical trials (2003-2014): progress and critical areas for improvement.
    J Urol. 2018 Sep 12. pii: S0022-5347(18)43872-4. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  559. RAJARUBENDRA N, Almeida F, Manojlovic Z, Ohe C, et al
    Histologic Validation of (11)Carbon-Acetate Positron Emission Tomography/Computer Tomography in Detecting Lymph Node Metastases in Prostate Cancer.
    J Urol. 2018 Sep 12. pii: S0022-5347(18)43871-2. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  560. OISHI M, Shin T, Ohe C, Nassiri N, et al
    Which Patients with Negative Magnetic Resonance Imaging Can Safely Avoid Biopsy for Prostate Cancer?
    J Urol. 2018 Sep 3. pii: S0022-5347(18)43794-9. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  561. KORNBERG Z, Cowan JE, Westphalen AC, Cooperberg MR, et al
    Genomic Prostate Score, PI-RADSv2, and Progression in Men with Prostate Cancer on Active Surveillance.
    J Urol. 2018 Sep 1. pii: S0022-5347(18)43795-0. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  562. ANDRIOLE GL, Kostakoglu L, Chau A, Duan F, et al
    The Impact of Positron Emission Tomography with (18)F-Fluciclovine on the Management of Patients with Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.
    J Urol. 2018 Sep 1. pii: S0022-5347(18)43798-6. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  563. GREGG JR, Lopez DS, Reichard C, Zheng J, et al
    Coffee, Caffeine Metabolism Genotype, and Disease Progression in Localized Prostate Cancer Patients Managed with Active Surveillance.
    J Urol. 2018 Sep 1. pii: S0022-5347(18)43796-2. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  564. ATALA A
    Re: An Aberrant SREBP-Dependent Lipogenic Program Promotes Metastatic Prostate Cancer.
    J Urol. 2018;200:501-502.
    PubMed    


  565. TANEJA SS
    Re: Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-Term Oncologic Outcomes in a Shared Equal-Access Health System.
    J Urol. 2018;200:499.
    PubMed    


  566. TANEJA SS
    Re: Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.
    J Urol. 2018;200:498-499.
    PubMed    


  567. TANEJA SS
    Re: Comparison between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer with Adverse Pathological Features.
    J Urol. 2018;200:497-499.
    PubMed    


  568. RESNICK MJ
    Re: Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.
    J Urol. 2018;200:488-489.
    PubMed    


  569. BOEHM K
    Editorial Comment.
    J Urol. 2018;200:557.
    PubMed    


  570. BARR RG
    Editorial Comment.
    J Urol. 2018;200:557-558.
    PubMed    


  571. MARKS LS
    Editorial Comment.
    J Urol. 2018;200:563.
    PubMed    


  572. LUDVIGSON A, Sammon J
    Editorial Comment.
    J Urol. 2018;200:581.
    PubMed    


  573. PINTHUS JH
    Editorial Comment.
    J Urol. 2018;200:580.
    PubMed    


  574. XU AJ, Taksler GB, Llukani E, Lepor H, et al
    Long-Term Continence Outcomes in Men Undergoing Radical Prostatectomy: A Prospective 15-Year Longitudinal Study.
    J Urol. 2018;200:626-632.
    PubMed     Abstract available


  575. BABALOLA O, Lee TJ, Viviano CJ
    Prostate Ablation Using High Intensity Focused Ultrasound: A Literature Review of the Potential Role for Patient Preference Information.
    J Urol. 2018;200:512-519.
    PubMed     Abstract available


  576. GUO DP, Thomas IC, Mittakanti HR, Shelton JB, et al
    The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration.
    J Urol. 2018;200:541-548.
    PubMed     Abstract available


    August 2018
  577. BERLIN A, Moraes FY, Sanmamed N, Glicksman R, et al
    International multi-center validation of an intermediate-risk subclassification of prostate cancer treated with radical treatment without hormone therapy.
    J Urol. 2018 Aug 25. pii: S0022-5347(18)43782-2. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  578. FAIENA I, Salmasi A, Mendhiratta N, Markovic D, et al
    PI-RADSv2 Category on 3 Tesla Multiparametric Prostate MRI Predicts Oncologic Outcomes in Gleason 3+4 Prostate Cancer on Biopsy.
    J Urol. 2018 Aug 21. pii: S0022-5347(18)43729-9. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  579. LOUGHLIN KR
    Serum Testosterone Levels and Prostate Cancer Risk: A Single Post-Hoc Testosterone Measurement is not Informative.
    J Urol. 2018 Aug 18. pii: S0022-5347(18)43724-X. doi: 10.1016/j.juro.2018.
    PubMed    


  580. DRUSKIN SC, Mamawala M, Tosoian JJ, Epstein JI, et al
    Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance.
    J Urol. 2018 Aug 13. pii: S0022-5347(18)43703-2. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  581. LOWRANCE WT, Murad MH, Oh WK, Jarrard DF, et al
    Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018.
    J Urol. 2018 Aug 4. pii: S0022-5347(18)43671-3. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  582. CRAWFORD ED, Koo PJ, Shore N, Slovin SF, et al
    A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence [RADAR] III).
    J Urol. 2018 Aug 2. pii: S0022-5347(18)43643-9. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  583. DEAN LW, Assel M, Sjoberg DD, Vickers AJ, et al
    Clinical utility of total length Gleason pattern 4 on biopsy in men with Grade Group 2 prostate cancer.
    J Urol. 2018 Aug 1. pii: S0022-5347(18)43632-4. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  584. KEARNS JT, Faino AV, Schenk JM, Newcomb LF, et al
    Continued Five-Alpha Reductase Inhibitor Use After Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the Canary Prostate Active Surveillance Study (PASS).
    J Urol. 2018 Aug 1. pii: S0022-5347(18)43635-X. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  585. WINQUIST E
    Editorial Comment.
    J Urol. 2018;200:351-352.
    PubMed    


  586. SAAD F
    Editorial Comment.
    J Urol. 2018;200:352.
    PubMed    


  587. STATTIN P
    Editorial Comment.
    J Urol. 2018;200:325-326.
    PubMed    


  588. LEHRER S
    Editorial Comment.
    J Urol. 2018;200:334.
    PubMed    


  589. WANG NN, Sonn GA
    Editorial Comment.
    J Urol. 2018;200:318.
    PubMed    


  590. DOMINGUEZ-ESCRIG JL
    Editorial Comment.
    J Urol. 2018;200:317-318.
    PubMed    


  591. CRAWFORD ED
    Editorial Comment.
    J Urol. 2018;200:343.
    PubMed    


  592. JIANG P, Liss MA, Szabo RJ
    Targeted Antimicrobial Prophylaxis Does Not Always Prevent Sepsis after Transrectal Prostate Biopsy.
    J Urol. 2018;200:361-368.
    PubMed     Abstract available


    July 2018
  593. BLOOM JB, Hale G, Gold SA, Rayn K, et al
    Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: The Role of a Negative Confirmatory MRI-US Fusion Biopsy.
    J Urol. 2018 Jul 28. pii: S0022-5347(18)43606-3. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  594. HUANG H, Muscatelli S, Naslund M, Badiyan SN, et al
    Evaluation of Cancer-Specific Mortality with Surgery Versus Radiation as Primary Therapy for Localized High-Grade Prostate Cancer in Men Younger than 60 Years Old.
    J Urol. 2018 Jul 27. pii: S0022-5347(18)43599-9. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  595. BASS R, Fleshner N, Finelli A, Barkin J, et al
    Oncologic and functional outcome of partial gland ablation with HIFU for localized prostate cancer.
    J Urol. 2018 Jul 20. pii: S0022-5347(18)43550-1. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  596. GOVERS T, Caba L, Resnick MJ
    Cost-Effectiveness of SelectMDx in Prostate Cancer Risk Assessment.
    J Urol. 2018 Jul 13. pii: S0022-5347(18)43530-6. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  597. TRUONG M
    Editorial Comment.
    J Urol. 2018;200:113.
    PubMed    


  598. CARLSSON S
    Editorial Comment.
    J Urol. 2018;200:87.
    PubMed    


  599. RESNICK MJ
    Editorial Comment.
    J Urol. 2018;200:80-81.
    PubMed    


  600. HUEN KH, Bergman J
    Editorial Comment.
    J Urol. 2018;200:80.
    PubMed    


  601. ROSENKRANTZ AB, Hemingway J, Hughes DR, Duszak R Jr, et al
    Evolving Use of Prebiopsy Prostate Magnetic Resonance Imaging in the Medicare Population.
    J Urol. 2018;200:89-94.
    PubMed     Abstract available


  602. GORDETSKY JB, Rais-Bahrami S
    Editorial Comment.
    J Urol. 2018;200:112-113.
    PubMed    


  603. BHINDI B, Wallis CJD
    Editorial Comment.
    J Urol. 2018;200:125.
    PubMed    


  604. BAYNE CE
    Re: Missed Opportunities to Decrease Radiation Exposure in Children with Renal Trauma: T. W. Gaither, M. A. Awad, N. V. Leva, G. P. Murphy, B. N. Breyer and H. L. Copp J Urol 2018;199:552-557.
    J Urol. 2018;200:205-206.
    PubMed    


  605. SCIALPI M, D'Andrea A, Aisa MC, Malaspina CM, et al
    Re: Risk Stratification of Equivocal Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: T. Ullrich, M. Quentin, C. Arsov, A. K. Schmaltz, A. Tschischka, N. Laqua, A. Hiester, D. Blondin, R. Rabenalt, P. Albers, G. Antoch and L. Sch
    J Urol. 2018;200:202-204.
    PubMed    


    June 2018
  606. RICHARDS KA, Liou JI, Cryns VL, Downs TM, et al
    Metformin Use Is Associated with Improved Survival in Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy.
    J Urol. 2018 Jun 22. pii: S0022-5347(18)43412-X. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  607. LEYH-BANNURAH SR, Kachanov M, Beyersdorff D, Preisser F, et al
    Anterior localization of prostate cancer suspicious MRI lesions in patients undergoing initial and repeat biopsy: Results from 1,161 patients undergoing MRI/ultrasound fusion-guided targeted biopsies.
    J Urol. 2018 Jun 20. pii: S0022-5347(18)43405-2. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  608. MARZOUK K, Assel M, Ehdaie B, Vickers A, et al
    Long term cancer-specific anxiety in men undergoing active surveillance for prostate cancer: findings from a large prospective cohort.
    J Urol. 2018 Jun 7. pii: S0022-5347(18)43349-6. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  609. LEPPERT JT, Asch SM, Bergman J
    Ethical Pitfalls When Estimating Life Expectancy For Patients with Prostate Cancer.
    J Urol. 2018 Jun 6. pii: S0022-5347(18)43328-9. doi: 10.1016/j.juro.2018.
    PubMed    


  610. TANEJA SS
    Re: Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-Effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS).
    J Urol. 2018;199:1397-1398.
    PubMed    


  611. TANEJA SS
    Re: Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
    J Urol. 2018;199:1396-1398.
    PubMed    


  612. GRIEBLING TL
    Re: Potential Overtreatment among Men Aged 80 Years and Older with Localized Prostate Cancer in Japan.
    J Urol. 2018;199:1375.
    PubMed    


  613. GRIEBLING TL
    Re: Safety and Feasibility of Robot-Assisted Radical Prostatectomy for Clinically Localized Prostate Cancer in Elderly Japanese Patients.
    J Urol. 2018;199:1375-1376.
    PubMed    


  614. GRIEBLING TL
    Re: Long-Term Survival of Patients Aged 80 Years or Older Treated with Radical Prostatectomy for Prostate Cancer.
    J Urol. 2018;199:1374.
    PubMed    


  615. GRIEBLING TL
    Re: Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology.
    J Urol. 2018;199:1373-1376.
    PubMed    


  616. GILL IS, Azzouzi AR, Emberton M, Coleman JA, et al
    Randomized Trial of Partial Gland Ablation with Vascular-Targeted Phototherapy versus Active Surveillance for Low-risk Prostate Cancer: Extended Follow-up and Analyses of Effectiveness.
    J Urol. 2018 Jun 1. pii: S0022-5347(18)43299-5. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


    May 2018
  617. RAYN KN, Bloom JB, Gold SA, Hale GR, et al
    Added Value of Multiparametric Magnetic Resonance Imaging to Clinical Nomograms in Predicting Adverse Pathology in Prostate Cancer.
    J Urol. 2018 May 28. pii: S0022-5347(18)43271-5. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  618. WEINER AB, Tsai KP, Keeter MK, Victorson DE, et al
    The Influence of decision aids on prostate cancer screening preferences: A randomized survey study.
    J Urol. 2018 May 28. pii: S0022-5347(18)43270-3. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  619. AMINSHARIFI A, Howard L, Wu Y, De Hoedt A, et al
    Prostate-specific antigen density as a predictor of clinically significant prostate cancer when the PSA level is in the diagnostic "grey-zone": Defining the optimum cut-point stratified by race and body mass index.
    J Urol. 2018 May 11. pii: S0022-5347(18)43126-6. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  620. HOFBAUER SL, Kittner B, Maxeiner A, Heckmann R, et al
    Validation of PI-RADS version 2 for the detection of prostate cancer.
    J Urol. 2018 May 4. pii: S0022-5347(18)43099-6. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  621. CRAWFORD ED, Schellhammer PF, McLeod DG, Moul JW, et al
    Androgen Receptor-Targeted Treatments for Prostate Cancer: 35 Years' Progress with Antiandrogens.
    J Urol. 2018 May 3. pii: S0022-5347(18)43086-8. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  622. TANEJA SS
    Re: Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-Deficient Prostate Cancer.
    J Urol. 2018;199:1113.
    PubMed    


  623. TANEJA SS
    Re: Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.
    J Urol. 2018;199:1112-1113.
    PubMed    


  624. SIEGEL C
    Re: Role of MRI in the Use of an Absorbable Hydrogel Spacer in Men Undergoing Radiation Therapy for Prostate Cancer: What the Radiologist Needs to Know.
    J Urol. 2018;199:1092.
    PubMed    


    April 2018
  625. RAVI P, Karnes RJ, Rangel LJ, Pagliaro LC, et al
    Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
    J Urol. 2018 Apr 27. pii: S0022-5347(18)43071-6. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  626. LARSEN LK, Jakobsen JS, Abdul-Al A, Guldberg P, et al
    Noninvasive detection of high-grade prostate cancer by DNA-methylation analysis of urine cells captured by microfiltration.
    J Urol. 2018 Apr 24. pii: S0022-5347(18)43047-9. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  627. PATEL HD, Gupta M, Tosoian JJ, Carter HB, et al
    Subtyping the Risk of Intermediate-Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy.
    J Urol. 2018 Apr 16. pii: S0022-5347(18)42985-0. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  628. GILD P, Cole AP, Krasnova A, Dickerman BA, et al
    Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer.
    J Urol. 2018 Apr 16. pii: S0022-5347(18)42984-9. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  629. RYAN CJ, Crawford ED, Shore ND, Underwood W 3rd, et al
    The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate-Specific Antigen and Radiographic Disease Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer.
    J Urol. 2018 Apr 6. pii: S0022-5347(18)42900-X. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  630. ATALA A
    Re: Prostate Cancer-Associated SPOP Mutations Confer Resistance to BET Inhibitors through Stabilization of BRD4.
    J Urol. 2018;199:895-896.
    PubMed    


  631. TANEJA SS
    Re: Cabazitaxel versus Docetaxel as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
    J Urol. 2018;199:893-894.
    PubMed    


  632. TANEJA SS
    Re: Health-Related Quality of Life for Immediate versus Delayed Androgen-Deprivation Therapy in Patients with Asymptomatic, Non-Curable Prostate Cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): A Randomised, Multicentre, Non-Blinded, Phase 3 Trial.
    J Urol. 2018;199:892-894.
    PubMed    


  633. CADEDDU JA
    Re: Robotic Salvage Retroperitoneal and Pelvic Lymph Node Dissection for 'Node-Only' Recurrent Prostate Cancer: Technique and Initial Series.
    J Urol. 2018;199:875-876.
    PubMed    


  634. SIEGEL C
    Re: Functional and Targeted Lymph Node Imaging in Prostate Cancer: Current Status and Future Challenges.
    J Urol. 2018;199:873.
    PubMed    


    March 2018
  635. WEI C, Li C, Szewczyk-Bieda M, Upreti D, et al
    Performance characteristics of transrectal shear wave elastography (SWE) imaging in the evaluation of clinically localised prostate cancer: a prospective study.
    J Urol. 2018 Mar 29. pii: S0022-5347(18)42856-X. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  636. SHAH N, Ioffe V
    Re: Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013: K. A. Houston, J. King, J. Li and A. Jemal J Urol 2018;199:676-682.
    J Urol. 2018 Mar 26. pii: S0022-5347(18)42402.
    PubMed    


  637. PATEL N, Hu JC
    Re: Recent Changes in Prostate Cancer Screening Practices and Epidemiology: D. J. Lee, K. Mallin, A. J. Graves, S. S. Chang, D. F. Penson, M. J. Resnick and D. A. Barocas J Urol 2017;198:1230-1240.
    J Urol. 2018 Mar 16. pii: S0022-5347(18)30117-4. doi: 10.1016/j.juro.2018.
    PubMed    


  638. KLOTZ L, Loblaw A, Siemens R, Ouellette P, et al
    A phase II, randomized, multicentre study comparing 10 months versus 4 months of degarelix (Firmagon(R)) therapy in prolonging the off treatment interval in men with localized prostate cancer receiving intermittent androgen deprivation therapy for bio
    J Urol. 2018 Mar 10. pii: S0022-5347(18)42502-5. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  639. RANDALL S, Boyd J, Fuller E, Brooks C, et al
    The effect of vasectomy reversal on prostate cancer risk: International meta-analysis of 684,660 men with vasectomies.
    J Urol. 2018 Mar 7. pii: S0022-5347(18)42489-5. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  640. PATEL N, Halpern JA, Kasabwala K, Cricco-Lizza E, et al
    Multiple regions of interest on multi-parametric magnetic resonance imaging are not associated with increased detection of clinically significant prostate cancer on fusion biopsy.
    J Urol. 2018 Mar 5. pii: S0022-5347(18)42470-6. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


    February 2018
  641. VAN STAM MA, Pieterse AH, van der Poel HG, Bosch JLHR, et al
    Shared Decision-Making in Prostate Cancer Care: Encouraging every patient to be actively involved in decision-making, or ensuring patients' preferred level of involvement?
    J Urol. 2018 Feb 28. pii: S0022-5347(18)42403.
    PubMed     Abstract available


  642. SAMPURNO F, Zheng J, Di Stefano L, Millar JL, et al
    Quality indicators for global benchmarking of localised prostate cancer management.
    J Urol. 2018 Feb 22. pii: S0022-5347(18)39377-7. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  643. MARZOUK S, Naglie G, Tomlinson G, Duff Canning S, et al
    Impact of Androgen Deprivation Therapy on Self-reported Cognitive Function in Men with Prostate Cancer.
    J Urol. 2018 Feb 22. pii: S0022-5347(18)39379-0. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  644. MORTEZAVI A, Marzendorfer O, Donati OF, Rizzi G, et al
    Diagnostic accuracy of mpMRI and fusion-guided targeted biopsy evaluated by transperineal template saturation prostate biopsy for the detection and characterization of prostate cancer.
    J Urol. 2018 Feb 20. pii: S0022-5347(18)39373-X. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  645. BAPAT B
    Re: Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance: F. Zhao, E. Olkhov-Mitsel, T. van der Kwast, J. Sykes, D. Zdravic, V. Venkateswaran, A. R. Zlotta, A. Lobl
    J Urol. 2018 Feb 8. pii: S0022-5347(18)30001-6. doi: 10.1016/j.juro.2017.
    PubMed    


  646. OZGUR BC
    Re: The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer: M. J. Mayer, L. H. Klotz and V. Venkateswaran J Urol 2017;197:1068-1075.
    J Urol. 2018 Feb 8. pii: S0022-5347(17)78117-7. doi: 10.1016/j.juro.2017.
    PubMed    


  647. NABHANI JA, Kuang R, Liu H, Kwan L, et al
    Health Changes in Low-income Men Transitioning from a State-funded Prostate Cancer Program to Comprehensive Insurance.
    J Urol. 2018 Feb 6. pii: S0022-5347(18)30183-6. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  648. ATALA A
    Re: mTORC1-Dependent AMD1 Regulation Sustains Polyamine Metabolism in Prostate Cancer.
    J Urol. 2018;199:344-346.
    PubMed    


  649. TANEJA SS
    Re: Follow-up of Prostatectomy versus Observation for Early Prostate Cancer.
    J Urol. 2018;199:342-343.
    PubMed    


  650. SEFTEL AD
    Re: The Accuracy of Patients' Perceptions of the Risks Associated with Localised Prostate Cancer Treatments.
    J Urol. 2018;199:329.
    PubMed    


  651. SIEGEL C
    Re: Pattern and Distribution of Distant Metastases in Anaplastic Prostate Carcinoma: A Single-Institute Experience with 101 Patients.
    J Urol. 2018;199:325.
    PubMed    


  652. SUN M, Cole AP, Hanna N, Mucci LA, et al
    Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis.
    J Urol. 2018 Feb 1. pii: S0022-5347(18)30109-5. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


    January 2018
  653. LOPCI E, Saita A, Lazzeri M, Lughezzani G, et al
    (68)Ga-PSMA PET/CT for primary diagnosis of prostate cancer in men with contraindications to or negative mpMRI: a prospective observational study.
    J Urol. 2018 Jan 31. pii: S0022-5347(18)30172-1. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  654. LUNDGREN PO, Kjellman A, Norming U, Gustafsson O, et al
    Long-term outcome of a single intervention Population based Prostate Cancer Screening Study.
    J Urol. 2018 Jan 31. pii: S0022-5347(18)30173-3. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  655. PRENDEVILLE S, Gertner M, Maganti M, Pintilie M, et al
    Role of MRI-targeted Biopsy in Detection of Prostate Cancer Harbouring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma.
    J Urol. 2018 Jan 31. pii: S0022-5347(18)30175-7. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  656. LEE JS, Lee HS, Ha JS, Han KS, et al
    Subcutaneous fat distribution is a prognostic biomarker for men with castration-resistant prostate cancer.
    J Urol. 2018 Jan 20. pii: S0022-5347(18)30106-X. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  657. CHALFIN HJ, Glavaris SA, Malihi PD, Sperger JM, et al
    Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Localized Patients Undergoing Radical Prostatectomy Across Multiple Rare Cell Detection Platforms.
    J Urol. 2018 Jan 12. pii: S0022-5347(18)30065-X. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  658. SANDA MG, Cadeddu JA, Kirkby E, Chen RC, et al
    Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options.
    J Urol. 2018 Jan 10. pii: S0022-5347(18)30014-4. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  659. NGUYEN DP, Vertosick EA, Sharma V, Corradi RB, et al
    Does subclassification of pathologically organ-confined (pT2) prostate cancer provide prognostic discrimination of outcomes after radical prostatectomy?
    J Urol. 2018 Jan 4. pii: S0022-5347(18)30005-3. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  660. KAPLAN SA
    Re: Long-Term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.
    J Urol. 2018;199:7-8.
    PubMed    


  661. TANEJA SS
    Re: Surrogate End Points for All-Cause Mortality in Men with Localized Unfavorable-Risk Prostate Cancer Treated with Radiation Therapy vs Radiation Therapy plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial.
    J Urol. 2018;199:28.
    PubMed    


  662. TANEJA SS
    Re: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
    J Urol. 2018;199:26-28.
    PubMed    


  663. PENSON DF
    Re: Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.
    J Urol. 2018;199:19-20.
    PubMed    


  664. CADEDDU JA
    Re: Near-Infrared Intraoperative Molecular Imaging Can Identify Metastatic Lymph Nodes in Prostate Cancer.
    J Urol. 2018;199:13-14.
    PubMed    


  665. SALAMI SS
    Editorial Comment.
    J Urol. 2018;199:104.
    PubMed    


  666. SONN G
    Editorial Comment.
    J Urol. 2018;199:104-105.
    PubMed    


  667. GHANI KR, Miller DC, Montie JE
    Editorial Comment.
    J Urol. 2018;199:96-97.
    PubMed    


  668. JOHNSON DC, Litwin MS
    Editorial Comment.
    J Urol. 2018;199:96.
    PubMed    


  669. PATEL NA, Kasabwala K, Hu JC
    Editorial Comment.
    J Urol. 2018;199:138-139.
    PubMed    


  670. NAHAR B, Parekh DJ
    Editorial Comment.
    J Urol. 2018;199:138.
    PubMed    


  671. BHINDI B
    Editorial Comment.
    J Urol. 2018;199:87-88.
    PubMed    


  672. KAPOOR DA
    A History of the United States Preventive Services Task Force: Its Expanding Authority and Need for Reform.
    J Urol. 2018;199:37-39.
    PubMed    


  673. TETREAULT-LAFLAMME A, Crook J, Hamm J, Pickles T, et al
    Long-Term Prostate Specific Antigen Stability and Predictive Factors of Failure after Permanent Seed Prostate Brachytherapy.
    J Urol. 2018;199:120-125.
    PubMed     Abstract available


  674. LUDWIG WW, Feng Z, Trock BJ, Humphreys E, et al
    Prostate Specific Antigen Testing after Radical Prostatectomy-Can We Stop at 20 Years?
    J Urol. 2018;199:114-119.
    PubMed     Abstract available


    December 2017
  675. OROM H, Biddle C, Underwood W 3rd, Nelson CJ, et al
    Worse urinary, sexual, and bowel function cause emotional distress and vice versa in men treated for prostate cancer.
    J Urol. 2017 Dec 26. pii: S0022-5347(17)78180-3. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  676. BERNSTEIN AN, Shoag JE, Golan R, Halpern JA, et al
    Contemporary Incidence & Outcomes of Prostate Cancer Lymph Node Metastases.
    J Urol. 2017 Dec 26. pii: S0022-5347(17)78181-5. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  677. AGHAZADEH MA, Frankel J, Belanger M, McLaughlin T, et al
    NCCN Favorable Intermediate Risk Prostate Cancer Patients: Is Active Surveillance Appropriate?
    J Urol. 2017 Dec 26. pii: S0022-5347(17)78182-7. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  678. LIU RSC, Olkhov-Mitsel E, Jeyapala R, Zhao F, et al
    Assessment of serum microRNA biomarkers for predicting reclassification of prostate cancer patients on active surveillance.
    J Urol. 2017 Dec 12. pii: S0022-5347(17)78068-8. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  679. VASAVADA SR, Dobbs RW, Kajdacsy-Balla AA, Abern MR, et al
    Inflammation on Prostate Needle Biopsy is Associated with Lower Prostate Cancer Risk: A Meta-Analysis.
    J Urol. 2017 Dec 12. pii: S0022-5347(17)78097-4. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  680. GEARMAN DJ, Morlacco A, Cheville JC, Rangel LJ, et al
    Comparison of Pathological and Oncologic Outcomes in "Favorable Risk" GS 3+4 and Low Risk GS6 Prostate Cancer: Considerations for Active Surveillance.
    J Urol. 2017 Dec 7. pii: S0022-5347(17)78036-6. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  681. ATALA A
    Re: Genomic Hallmarks of Localized, Non-Indolent Prostate Cancer.
    J Urol. 2017;198:1213.
    PubMed    


  682. ATALA A
    Re: The Metabolic Co-Regulator PGC1alpha Suppresses Prostate Cancer Metastasis.
    J Urol. 2017;198:1212-1214.
    PubMed    


  683. TANEJA SS
    Re: Associations of Luminal and Basal Subtyping of Prostate Cancer with Prognosis and Response to Androgen Deprivation Therapy.
    J Urol. 2017;198:1211.
    PubMed    


  684. TANEJA SS
    Re: Association between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.
    J Urol. 2017;198:1210-1211.
    PubMed    


  685. TANEJA SS
    Re: Impact of Ga-68 PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer.
    J Urol. 2017;198:1209-1210.
    PubMed    


  686. TANEJA SS
    Re: Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories.
    J Urol. 2017;198:1208-1211.
    PubMed    


  687. MOREY AF
    Re: Radiation-Induced Complex Anterior Urinary Fistulation for Prostate Cancer: A Retrospective Multicenter Study from the Trauma and Urologic Reconstruction Network of Surgeons (TURNS).
    J Urol. 2017;198:1201-1203.
    PubMed    


  688. PENSON DF
    Re: Treatment Decision Regret among Long-Term Survivors of Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study.
    J Urol. 2017;198:1200.
    PubMed    


  689. SANDA MG, Cadeddu JA, Kirkby E, Chen RC, et al
    Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline, PART I.
    J Urol. 2017 Dec 1. pii: S0022-5347(17)78003-2. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


    November 2017
  690. HASSAN O, Han M, Zhou A, Paulk A, et al
    Incidence of Extra-Prostatic Extension at Radical Prostatectomy with Pure Gleason Score 3+3=6 (Grade Group 1) Cancer: Implications for Whether Gleason Score 6 Prostate Cancer Should be Renamed as "not Cancer" and for Selection Criteria for Active Surv
    J Urol. 2017 Nov 15. pii: S0022-5347(17)77915-3. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  691. PISHGAR F, Ebrahimi H, Moghaddam SS, Fitzmaurice C, et al
    Global, Regional and National Burden of Prostate Cancer, 1990 - 2015: Results from the Global Burden of Disease Study 2015.
    J Urol. 2017 Nov 9. pii: S0022-5347(17)77883-4. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  692. TANEJA SS
    Re: Weight Change, Obesity and Risk of Prostate Cancer Progression among Men with Clinically Localized Prostate Cancer.
    J Urol. 2017;198:982.
    PubMed    


  693. TANEJA SS
    Re: Effective Combinatorial Immunotherapy for Castration-Resistant Prostate Cancer.
    J Urol. 2017;198:982-983.
    PubMed    


  694. TANEJA SS
    Re: Prognostic Utility of Biopsy-Derived Cell Cycle Progression Score in Patients with National Comprehensive Cancer Network Low-Risk Prostate Cancer Undergoing Radical Prostatectomy: Implications for Treatment Guidance.
    J Urol. 2017;198:981.
    PubMed    


  695. TANEJA SS
    Re: Treatment Decision Regret among Long-Term Survivors of Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study.
    J Urol. 2017;198:980-983.
    PubMed    


    October 2017
  696. HALPERN JA, Oromendia C, Shoag JE, Mittal S, et al
    Utility of Digital Rectal Examination (DRE) as an Adjunct to Prostate Specific Antigen (PSA) in the Detection of Clinically Significant Prostate Cancer.
    J Urol. 2017 Oct 20. pii: S0022-5347(17)77762-2. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  697. AUDENET F, Vertosick EA, Fine SW, Sjoberg DD, et al
    Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer.
    J Urol. 2017 Oct 10. pii: S0022-5347(17)77714-2. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  698. ATALA A
    Re: Genome-Wide Association Study of Prostate-Specific Antigen Levels Identifies Novel Loci Independent of Prostate Cancer.
    J Urol. 2017;198:747.
    PubMed    


  699. TANEJA SS
    Re: Presence of Invasive Cribriform or Intraductal Growth at Biopsy Outperforms Percentage Grade 4 in Predicting Outcome of Gleason Score 3+4=7 Prostate Cancer.
    J Urol. 2017;198:745.
    PubMed    


  700. PENSON DF
    Re: Association between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes after 3 Years.
    J Urol. 2017;198:744-745.
    PubMed    


  701. TANEJA SS
    Re: Association between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes after 3 Years.
    J Urol. 2017;198:743-744.
    PubMed    


  702. TANEJA SS
    Re: Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
    J Urol. 2017;198:742-743.
    PubMed    


  703. TANEJA SS
    Re: Active Surveillance in Younger Men with Prostate Cancer.
    J Urol. 2017;198:741-745.
    PubMed    


  704. PENSON DF
    Re: Sharp Decline in Prostate Cancer Treatment among Men in the General Population, but Not among Diagnosed Men.
    J Urol. 2017;198:734-735.
    PubMed    


  705. GRIEBLING TL
    Re: Current Impact of Age and Comorbidity Assessment on Prostate Cancer Treatment Choice and Over/Undertreatment Risk.
    J Urol. 2017;198:724.
    PubMed    


  706. GRIEBLING TL
    Re: Comorbidity and Age Cannot Explain Variation in Life Expectancy Associated with Treatment of Non-Metastatic Prostate Cancer.
    J Urol. 2017;198:723.
    PubMed    


  707. GRIEBLING TL
    Re: Which Better Predicts Mortality among Older Men, a Prostate Cancer (PCa) Diagnosis or Vulnerability on the Vulnerable Elders Survey (VES-13)? A Retrospective Cohort Study.
    J Urol. 2017;198:723-724.
    PubMed    


    September 2017
  708. HOUSTON KA, King J, Li J, Jemal A, et al
    Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate-Specific Antigen Screening by Socioeconomic Status and Regions in the US, 2004- 2013.
    J Urol. 2017 Sep 28. pii: S0022-5347(17)77650-1. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  709. HEILBRUN LK, Powell IJ
    Re: Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy: M. S. Leapman, S. J. Freedland, W. J. Aronson, C. J. Kane, M. K. T
    J Urol. 2017 Sep 26. pii: S0022-5347(17)77419-8. doi: 10.1016/j.juro.2017.
    PubMed    


  710. TOSOIAN JJ, Carter HB
    Patients with Intermediate Risk Prostate Cancer May be Good Candidates for Active Surveillance: Con.
    J Urol. 2017 Sep 22. pii: S0022-5347(17)77388-0. doi: 10.1016/j.juro.2017.
    PubMed    


  711. SANDA MG
    Patients with Intermediate Risk Prostate Cancer May be Good Candidates for Active Surveillance: Pro.
    J Urol. 2017 Sep 22. pii: S0022-5347(17)77389-2. doi: 10.1016/j.juro.2017.
    PubMed    


  712. XU X, Zhang X, Zhong Y, Saad F, et al
    Dynamic Patterns of Testosterone Levels within Individuals and Risk of Prostate Cancer among Hypogonadal Men: A Longitudinal Study.
    J Urol. 2017 Sep 20. pii: S0022-5347(17)77561-1. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  713. NGUYEN HG, Welty C, Lindquist K, Ngo V, et al
    Validation of GEMCaP as a DNA based biomarker to predict prostate cancer recurrence after radical prostatectomy.
    J Urol. 2017 Sep 20. pii: S0022-5347(17)77554-4. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  714. SHIOTA M, Fujimoto N, Takeuchi A, Kashiwagi E, et al
    The association of polymorphisms in the gene encoding gonadotropin releasing hormone with serum testosterone level during androgen-deprivation therapy and prognosis in metastatic prostate cancer.
    J Urol. 2017 Sep 20. pii: S0022-5347(17)77562-3. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  715. NYAME YA, Grimberg DC, Greene DJ, Gupta K, et al
    Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active Surveillance.
    J Urol. 2017 Sep 20. pii: S0022-5347(17)77563-5. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  716. GARCIA-REYES K, Nguyen HG, Zagoria RJ, Shinohara K, et al
    Impact of lesion visibility on transrectal ultrasound on the prediction of clinically significant prostate cancer (Gleason score >/= 3+4) with TRUS-MRI fusion biopsy.
    J Urol. 2017 Sep 20. pii: S0022-5347(17)77560-X. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  717. NEHRA A, Parker WP, Haloi R, Park SS, et al
    Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using 11C-Choline Positron Emission Tomography and Multiparametric Pelvic MRI.
    J Urol. 2017 Sep 12. pii: S0022-5347(17)77497-6. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  718. ORCZYK C, Emberton M
    Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology: A. Priester, S. Natarajan, P. Khoshnoodi, D. J. Margolis, S. S. Raman, R. E. Reiter, J. Huang, W.
    J Urol. 2017 Sep 6. pii: S0022-5347(17)77256-4. doi: 10.1016/j.juro.2017.
    PubMed    


  719. ATALA A
    Re: MicroRNA-141 Suppresses Prostate Cancer Stem Cells and Metastasis by Targeting a Cohort of Pro-Metastasis Genes.
    J Urol. 2017;198:486.
    PubMed    


  720. ATALA A
    Re: AKT-Mediated Stabilization of Histone Methyltransferase WHSC1 Promotes Prostate Cancer Metastasis.
    J Urol. 2017;198:485-487.
    PubMed    


  721. TANEJA SS
    Re: Videotaping of Surgical Procedures and Outcomes following Extraperitoneal Laparoscopic Radical Prostatectomy for Clinically Localized Prostate Cancer.
    J Urol. 2017;198:483-484.
    PubMed    


  722. SEFTEL AD
    Re: Association between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes after 3 Years.
    J Urol. 2017;198:466-468.
    PubMed    


  723. TEETER AE, Griffin K, Howard LE, Aronson WJ, et al
    Does early PSADT (ePSADT) after Radical Prostatectomy, Calculated prior to PSA Recurrence, Correlate with Prostate Cancer Outcomes? -A Report from the SEARCH Database Group.
    J Urol. 2017 Sep 1. pii: S0022-5347(17)77427-7. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


    August 2017
  724. TOMBAL B, Borre M, Rathenborg P, Werbrouck P, et al
    Long-term Anti-tumor Activity and Safety of Enzalutamide Monotherapy in Hormone-naive Prostate Cancer: 3-year, Open-label, Follow-up Results.
    J Urol. 2017 Aug 31. pii: S0022-5347(17)77422-8. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  725. CASTELLO A, Boldo E, Amiano P, Castano-Vinyals G, et al
    Mediterranean dietary pattern is associated to low risk of aggressive prostate cancer: MCC-Spain study.
    J Urol. 2017 Aug 22. pii: S0022-5347(17)77385-5. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  726. SIEMENS DR, Klotz L, Heidenreich A, Chowdhury S, et al
    Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration-resistant Prostate Cancer in the TERRAIN Trial.
    J Urol. 2017 Aug 18. pii: S0022-5347(17)77377-6. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  727. GARCIA-BARRERAS S, Sanchez-Salas R, Sivaraman A, Barret E, et al
    Partial gland ablation versus radical prostatectomy Comparative Analysis of Partial Gland Ablation and Radical Prostatectomy to Treat Low- and Intermediate-risk Prostate Cancer: Oncologic and Functional Outcomes.
    J Urol. 2017 Aug 17. pii: S0022-5347(17)77373-9. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  728. SHRESTHA E, White JR, Yu SH, Kulac I, et al
    Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer.
    J Urol. 2017 Aug 7. pii: S0022-5347(17)77253-9. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  729. DAI C, Ganesan V, Zabell J, Nyame YA, et al
    Impact of 5alpha-reductase inhibitors on disease reclassification among men on active surveillance for localized prostate cancer with favorable features.
    J Urol. 2017 Aug 5. pii: S0022-5347(17)77259-X. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  730. AUFFENBERG GB, Lane BR, Linsell S, Brachulis A, et al
    A Roadmap for improving the management of men with favorable-risk prostate cancer.
    J Urol. 2017 Aug 3. pii: S0022-5347(17)77250-3. doi: 10.1016/j.juro.2017.
    PubMed    


  731. ATALA A
    Re: SOX2 Promotes Lineage Plasticity and Antiandrogen Resistance in TP53- and RB1-Deficient Prostate Cancer.
    J Urol. 2017;198:259.
    PubMed    


  732. TANEJA SS
    Re: Change in Salvage Radiotherapy Management Based on Guidance with FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer.
    J Urol. 2017;198:256-257.
    PubMed    


  733. TANEJA SS
    Re: Padeliporfin Vascular-Targeted Photodynamic Therapy versus Active Surveillance in Men with Low-Risk Prostate Cancer (CLIN1001 PCM301): An Open-Label, Phase 3, Randomised Controlled Trial.
    J Urol. 2017;198:255-257.
    PubMed    


    July 2017
  734. SAMMON JD, Serrell EC, Karabon P, Leow JJ, et al
    Prostate Cancer Screening in Early Medicaid Expansion States.
    J Urol. 2017 Jul 29. pii: S0022-5347(17)77241-2. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  735. TAPLIN ME, Armstrong AJ, Lin P, Krivoshik A, et al
    Clinical Outcomes of Chemotherapy-Naive Men with Metastatic Castration-Resistant Prostate Cancer and Low Baseline PSA Treated with Enzalutamide vs Placebo.
    J Urol. 2017 Jul 20. pii: S0022-5347(17)77187-X. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  736. TAMMELA TL, Haggman M, Ladjevardi S, Taari K, et al
    An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer.
    J Urol. 2017 Jul 20. pii: S0022-5347(17)77188-1. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  737. GORIN MA, Rowe SP, Patel HD, Vidal I, et al
    PSMA-targeted 18F-DCFPyL PET/CT in the Preoperative Staging of Men with High-risk Prostate Cancer: Results of a Prospective Phase II Single-Center Study.
    J Urol. 2017 Jul 20. pii: S0022-5347(17)77186-8. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  738. CHANG E, Jones TA, Natarajan S, Sharma D, et al
    Value of Tracking Biopsy in Men Undergoing Active Surveillance of Prostate Cancer.
    J Urol. 2017 Jul 17. pii: S0022-5347(17)77144-3. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  739. YANG L, Kibel AS, Colditz GA, Pakpahan R, et al
    Caution with Use of the Expanded Prostate Cancer Index Composite-50 Urinary Bother Scale: How Voiding Dysfunction Modifies Its Performance.
    J Urol. 2017 Jul 17. pii: S0022-5347(17)77147-9. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  740. STROUP SP, Moreira DM, Chen Z, Howard L, et al
    Biopsy-Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis, and Mortality in a Cohort of Men with High-Risk Prostate Cancer.
    J Urol. 2017 Jul 11. pii: S0022-5347(17)77098-X. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  741. PENSON DF
    Re: Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States.
    J Urol. 2017;198:104-105.
    PubMed    


  742. PENSON DF
    Re: Vasectomy and Prostate Cancer Incidence and Mortality in a Large US Cohort.
    J Urol. 2017;198:104-106.
    PubMed    


  743. ATALA A
    Re: Targeted Molecular-Genetic Imaging and Ligand-Directed Therapy in Aggressive Variant Prostate Cancer.
    J Urol. 2017;198:103-104.
    PubMed    


  744. ATALA A
    Re: Low CD38 Identifies Progenitor-Like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome.
    J Urol. 2017;198:103.
    PubMed    


  745. ATALA A
    Re: Rb1 and Trp53 Cooperate to Suppress Prostate Cancer Lineage Plasticity, Metastasis, and Antiandrogen Resistance.
    J Urol. 2017;198:102-104.
    PubMed    


  746. TANEJA SS
    Re: Diagnostic Accuracy of Multi-Parametric MRI and TRUS Biopsy in Prostate Cancer (PROMIS): A Paired Validating Confirmatory Study.
    J Urol. 2017;198:101-102.
    PubMed    


  747. TANEJA SS
    Re: Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
    J Urol. 2017;198:100-102.
    PubMed    


    June 2017
  748. BHINDI B, Karnes RJ, Rangel LJ, Mason RJ, et al
    Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification.
    J Urol. 2017 Jun 29. pii: S0022-5347(17)77027-9. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  749. JONES TA, Chin J, Mcleod D, Barkin J, et al
    High-Intensity Focused Ultrasound for Radio-recurrent Prostate Cancer: A North American Clinical Trial.
    J Urol. 2017 Jun 23. pii: S0022-5347(17)76734-1. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  750. PALAPATTU GS
    Genomic Tests Should be Used to Help Guide Treatment of Prostate Cancer: Yes.
    J Urol. 2017 Jun 16. pii: S0022-5347(17)67196-9. doi: 10.1016/j.juro.2017.
    PubMed    


  751. PUNNEN S, Parekh DJ
    Genomic Tests Should be Used to Help Guide Treatment of Prostate Cancer: No.
    J Urol. 2017 Jun 16. pii: S0022-5347(17)67197-0. doi: 10.1016/j.juro.2017.
    PubMed    


  752. KIBEL AS
    Intermediate Risk Prostate Cancer and Active Surveillance: Maximize Utilization while Minimizing Failure.
    J Urol. 2017 Jun 16. pii: S0022-5347(17)74842-2. doi: 10.1016/j.juro.2017.
    PubMed    


  753. SEFTEL AD
    Re: Rasch Analysis of the Premature Ejaculation Diagnostic Tool (PEDT) and the International Index of Erectile Function (IIEF) in an Iranian Sample of Prostate Cancer Patients.
    J Urol. 2017;197:1534-1535.
    PubMed    


  754. KAPLAN SA
    Re: Interactions between Benign Prostatic Hyperplasia (BPH) and Prostate Cancer in Large Prostates: A Retrospective Data Review.
    J Urol. 2017;197:1531-1532.
    PubMed    


  755. ATALA A
    Re: Androgen Receptor Antagonists Compromise T Cell Response against Prostate Cancer Leading to Early Tumor Relapse.
    J Urol. 2017;197:1459.
    PubMed    


  756. ATALA A
    Re: Activation of Notch1 Synergizes with Multiple Pathways in Promoting Castration-Resistant Prostate Cancer.
    J Urol. 2017;197:1458-1459.
    PubMed    


  757. CADEDDU JA
    Re: Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial.
    J Urol. 2017;197:1457-1458.
    PubMed    


  758. TANEJA SS
    Re: Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer.
    J Urol. 2017;197:1456.
    PubMed    


  759. TANEJA SS
    Re: Mortality among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.
    J Urol. 2017;197:1456-1457.
    PubMed    


  760. DENIZE J, Nouhaud FX, Cornu JN, Pfister C, et al
    Re: Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study: L. C. Macleod, W. J. Ellis, L. F. Newcomb, Y. Zheng, J. D. Brooks, P. R. Carroll, M. E. Gleave, R.
    J Urol. 2017 Jun 1. pii: S0022-5347(17)59378-7. doi: 10.1016/j.juro.2017.
    PubMed    


    May 2017
  761. YAN W, Shang Z, Zhou Z
    Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology: A. Priester, S. Natarajan, P. Khoshnoodi, D. J. Margolis, S. S. Raman, R. E. Reiter, J. Huang, W.
    J Urol. 2017 May 31. pii: S0022-5347(17)57834-9. doi: 10.1016/j.juro.2017.
    PubMed    


  762. TELOKEN PE, Li J, Woods CG, Cohen RJ, et al
    The impact of prostate cancer zonal origin on pathological parameters at radical prostatectomy and subsequent biochemical failure.
    J Urol. 2017 May 26. pii: S0022-5347(17)74541-7. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  763. TOMBAL B, Cornel EB, Persad R, Stari A, et al
    Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study.
    J Urol. 2017 May 25. pii: S0022-5347(17)74503-X. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  764. FELDMAN AS, Meyer CP, Sanchez A, Krasnova A, et al
    Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population-Based Analysis Comparing Radical Prostatectomy Versus External Beam Radiation.
    J Urol. 2017 May 25. pii: S0022-5347(17)74504-1. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  765. LEE DJ, Mallin K, Graves AJ, Chang SS, et al
    Recent changes in prostate cancer screening practices and prostate cancer epidemiology.
    J Urol. 2017 May 25. pii: S0022-5347(17)74517-X. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  766. HENRY MA, Howard DH, Davies BJ, Filson CP, et al
    Variation in Use of Prostate Biopsy Following Changes in Prostate Cancer Screening Guidelines.
    J Urol. 2017 May 6. pii: S0022-5347(17)64683-4. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  767. SEFTEL AD
    Re: Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    J Urol. 2017;197:1266.
    PubMed    


  768. TANEJA SS
    Re: Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    J Urol. 2017;197:1265-1266.
    PubMed    


  769. TANEJA SS
    Re: Development and Validation of a 24-Gene Predictor of Response to Postoperative Radiotherapy in Prostate Cancer: A Matched, Retrospective Analysis.
    J Urol. 2017;197:1264-1266.
    PubMed    


    April 2017
  770. GOLAN R, Bernstein AN, McClure TD, Sedrakyan A, et al
    Partial gland treatment of prostate cancer utilizing high-intensity focused ultrasound in the primary and salvage setting: a systematic review.
    J Urol. 2017 Apr 19. pii: S0022-5347(17)54786-2. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  771. NATARAJAN S, Jones TA, Priester AM, Geoghegan R, et al
    Focal Laser Ablation of Prostate Cancer: Feasibility of MRI/US Fusion for Guidance.
    J Urol. 2017 Apr 7. pii: S0022-5347(17)45433-4. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


    March 2017
  772. DISTLER FA, Radtke JP, Bonekamp D, Kesch C, et al
    The value of PSA density in combination with PI-RADS for the accuracy of prostate cancer prediction.
    J Urol. 2017 Mar 31. pii: S0022-5347(17)43846-8. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  773. MEHRALIVAND S, Bednarova S, Shih JH, Mertan FV, et al
    Prospective Evaluation of Prostate Imaging-Reporting and Data System Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System.
    J Urol. 2017 Mar 31. pii: S0022-5347(17)43847-X. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  774. NYAME YA, Almassi N, Haywood SC, Greene DJ, et al
    Intermediate-Term Outcomes of Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance.
    J Urol. 2017 Mar 24. pii: S0022-5347(17)42185-9. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  775. LEBDAI S, Bigot P, Leroux PA, Berthelot LP, et al
    Vascular-Targeted Photodynamic Therapy with Padeliporfin for Low Risk Prostate Cancer Treatment: Mid-Term Oncological Outcomes.
    J Urol. 2017 Mar 18. pii: S0022-5347(17)40346-6. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


    February 2017
  776. TANEJA SS
    Re: Study of Testosterone-Guided Androgen Deprivation Therapy in Management of Prostate Cancer.
    J Urol. 2017;197:398-399.
    PubMed    


    December 2016
  777. KAPLAN SA
    Re: Testosterone Replacement Therapy on the Natural History of Prostate Disease.
    J Urol. 2016;196:1713-1714.
    PubMed    


  778. SEFTEL AD
    Re: Variation in Testosterone Levels and Health-Related Quality of Life in Men Diagnosed with Prostate Cancer on Active Surveillance.
    J Urol. 2016;196:1723-1724.
    PubMed    


    June 2016
  779. KAPLAN SA
    Re: Resveratrol Reduces the Levels of Circulating Androgen Precursors but has No Effect on Testosterone, Dihydrotestosterone, PSA Levels or Prostate Volume. A 4-Month Randomised Trial in Middle-Aged Men.
    J Urol. 2016;195:1838.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: